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ABSTRACT: Discovery of the potent antileishmanial eﬀects
of antitubercular 6-nitro-2,3-dihydroimidazo[2,1-b][1,3]-
oxazoles and 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-
b][1,3]oxazines stimulated the examination of further scaﬀolds
(e.g. , 2-nitro-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]-
oxazepines), but the results for these seemed less attractive.
Following the screening of a 900-compound pretomanid
analogue library, several hits with more suitable potency,
solubility, and microsomal stability were identiﬁed, and the
superior eﬃcacy of newly synthesized 6R enantiomers with
phenylpyridine-based side chains was established through head-to-head assessments in a Leishmania donovani mouse model. Two
such leads (R-84 and R-89) displayed promising activity in the more stringent Leishmania infantum hamster model but were
unexpectedly found to be potent inhibitors of hERG. An extensive structure−activity relationship investigation pinpointed two
compounds (R-6 and pyridine R-136) with better solubility and pharmacokinetic properties that also provided excellent oral
eﬃcacy in the same hamster model (>97% parasite clearance at 25 mg/kg, twice daily) and exhibited minimal hERG inhibition.
Additional proﬁling earmarked R-6 as the favored backup development candidate.
■ INTRODUCTION
Visceral leishmaniasis (VL) is a particularly lethal sandﬂy-borne
parasitic disease that is prevalent in more than 60 countries,
where it mostly aﬀects underprivileged people in remote rural
areas who have limited access to diagnosis and treatment.1−3
Major outbreaks of VL in East Africa have been attributed to
waves of forced migration during periods of conﬂict, and such
epidemics are exacerbated by weak healthcare systems,
malnutrition, and HIV/AIDS coinfection.4,5 Moreover, in this
region, the ﬁrst-line drug combination of paromomycin and
sodium stibogluconate was found to be unsuitable for VL
patients who were >50 years of age or those with HIV, and no
other therapies have shown adequate eﬃcacy.6,7 Failure of the
most recently evaluated new agent, fexinidazole, in a phase II
clinical trial for VL in Sudan8 has now left the clinical pipeline
empty, underlining the compelling need to develop more
satisfactory medications.9
The target product proﬁle (TPP) of an optimized new
chemical entity for the treatment of VL requires (i)
eﬀectiveness against all causative species, in all endemic areas,
in both immunocompetent and immunosuppressed individuals,
with a clinical eﬃcacy of >95%; (ii) activity against resistant
strains; (iii) no adverse safety events requiring monitoring and
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no contraindications; (iv) no drug−drug interactions (suitable
for combination therapy); (v) oral administration once per day
for a maximum of 10 days (or intramuscular dosing three times
over 10 days); (vi) stability in relevant climates (3 years); and
(vii) aﬀordable cost (<$80, ideally <$10 per course).10
However, new drug discovery for VL faces formidable
challenges, such as inadequate investment, a lack of validated
targets, poor translation of in vitro activity into in vivo models,
and meager hit rates (<0.1%) for phenotypic screening of
compound libraries.11−13 The latter may be due in part to the
concealed location of parasites in acidic parasitophorous
vacuoles within macrophages.14 Furthermore, the unique
glycolipid-rich cell surface of the amastigotes presents an
additional barrier to chemotherapy.15 Another issue is that
many cellularly active hits may never meet TPP and
progression criteria, even after valiant optimization at-
tempts.13,16 Nevertheless, drug development eﬀorts spear-
headed by the Drugs for Neglected Diseases initiative
(DNDi) have now shown encouraging progress in several
novel classes, including oxaboroles and aminopyrazoles.12,17,18
Novartis has also disclosed a triazolopyrimidine preclinical lead
with utility in vivo against both leishmanial and trypanosomal
infections.19
The 2-nitroimidazooxazines are best known for their potent
eﬀects against Mycobacterium tuberculosis (M. tb), the causative
agent of tuberculosis (TB).20 The ﬁrst drug candidate from this
class, pretomanid [PA-824, S-1 (Figure 1)], has shown
excellent safety and bactericidal eﬃcacy in phase II clinical
trials for TB,21 leading to its ongoing combination assess-
ment,22 while our collaborative work with the TB Alliance on
second-generation analogues of S-1 culminated in the advance-
ment of TBA-354 (S-2) into phase I studies.23 We have
recently described the investigation of a novel 7-substituted 2-
nitroimidazooxazine class, which in addition to possessing
considerable potential against TB has also demonstrated
exciting activity against both VL and Chagas disease, resulting
in the selection of preclinical VL lead 3.24 This followed an in-
depth analysis of the structurally related 6-nitroimidazooxazole
class,25 where phenotypic screening of some of our initial
examples by DNDi had enabled the discovery of previous
development nominee 4 (DNDI-VL-2098).26 The latter was
found27 to be activated by a novel leishmanial nitroreductase
(NTR2). In comparison to 4, candidate 3 exhibited an
improved safety proﬁle and had similarly notable eﬃcacy in
two animal models of VL.24 Furthermore, while the new TB
drug delamanid (5) has also been suggested as a possible VL
therapy,28 it is noteworthy that 3 was substantially more
eﬀective than this agent in the highly stringent chronic infection
hamster model.24,25
As part of our VL lead optimization program with DNDi, it
was considered important to develop a few eﬃcacious backup
compounds having good physicochemical/pharmacological
proﬁles and better safety, to mitigate development risks.
Given the encouraging results with nitroimidazooxazoles and
7-substituted 2-nitroimidazooxazines, we ﬁrst evaluated various
other pretomanid-related scaﬀolds for VL, including those with
a reversed linker at C-629,30 and novel nitroimidazooxazepines.
We then assessed our larger collection of pretomanid analogues
via the medium-throughput screening of ∼900 compounds at
the Institut Pasteur Korea (IPK). Finally, a more systematic
synthetic approach was employed to redevelop the 6-
substituted 2-nitroimidazooxazine class for VL, taking into
consideration both enantiomer forms. We now report the
ﬁndings from these wide-ranging structure−activity relationship
(SAR) studies, including the detailed in vitro/in vivo proﬁling of
selected new leads, which resulted in our identiﬁcation of the
title compound as a very promising VL backup candidate.
■ CHEMISTRY
Scheme 1 outlines the synthetic methods used to prepare eight
novel racemic analogues of S-1 featuring changes to the original
nitroimidazooxazine core (14, 22, 23, 32, 33, 39, 40, and 47).
A common strategy (based on the original, well-validated route
to S-1 and simple derivatives)31,32 proved to be eﬀective for the
ﬁrst ﬁve of these (Scheme 1A−C), involving the initial reaction
of functionalized epoxides (9,33 17, and 2734) with 2,4-
dinitroimidazole (8), followed by THP protection of the
derived alcohols (10, 18, and 28). In the shorter chain cases
(11 and 19), subsequent cleavage of the TBS ether (TBAF)
enabled in situ annulation, whereas in the latter instance (29),
oxazepine ring formation required additional treatment with a
strong base (NaH). Removal of the THP group with
methanesulfonic acid and standard alkylation chemistry on
alcohols 13, 21, and 31 then gave the aforementioned targets.
For the isomeric oxazepines (Scheme 1D), THP protection
of alcohol 3424 and desilylation (TBAF) similarly furnished the
noncyclized alcohol 36, which was ring-closed (NaH and
DMF) and THP-deprotected (HCl) to produce alcohol 38.
However, both ﬁnal step alkylations of 38 unexpectedly
cogenerated signiﬁcant quantities (20−36%) of the isomeric
7-substituted oxazine derivative (41 or 42), together with the
desired oxazepine ether (39 or 40). Although this is
unconﬁrmed, it is postulated that this rearrangement may
involve an intramolecular SNAr reaction, with attack by the
oxazepine alkoxide anion at the imidazole ring junction carbon
9a and subsequent alkylation of the released 2-nitroimidazoox-
azine 7-alkoxide (but it should be emphasized that no similar
rearrangements were detected during the derivatization of 13,
21, 31, or the alcohol precursor to S-1, and that S-1 itself has
shown excellent safety and a lengthy 16−18 h half-life in clinical
trials for TB,35 suggesting that 2-nitroimidazooxazine-based VL
leads would be unlikely to demonstrate an excessive reactivity
toward biological nucleophiles; this is further supported by an
observed tolerance of the latter ring system toward several basic
nucleophiles in the chemistry reported below). The remaining
Figure 1. Structures of antitubercular or antileishmanial agents.
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scaﬀold, nitrotriazolooxazine 47, was accessed from 5-bromo-3-
nitro-1,2,4-triazole (43) and iodide 44,36 via desilylation/in situ
annulation of the major adduct 46, as shown above (Scheme
1E).
The assembly of new biaryl and heterobiaryl side chain
variants of S-1 and its enantiomer, R-1,37,38 was relatively
straightforward (Schemes 2 and 3). Biphenyl analogues (R-58,
R-60, and R-62) were created by Suzuki coupling reactions on
halobenzyl ether derivatives of the key 6-R alcohol 56,32 while
combination of 56 with bromide 6339 aﬀorded the terminal
pyridine R-64 (Scheme 2A). Alternative alkylation of 56 or its
6-S equivalent 6532 with various isomeric bromomethyl
bromopyridines (66, 71, 75, 82,39 and 97) then set up the
Suzuki-based manufacture of novel ortho-linked phenylpyr-
idines [S-69, R-69, S-74, and R-74 (Scheme 2B,C)] and both
meta- and para-linked congeners (Schemes 2D and 3A,C). This
latter work was further expanded to include examples
containing a pyridazine, pyrazine, or pyrimidine ring (R-109,
R-112, and R-115), using similar chemistry39 (Scheme 3D),
and to a novel racemic nitrotriazole counterpart of R-84 [88
(Scheme 3B)], starting from alcohol 86.40 Lastly, a buﬀered m-
CPBA oxidation of R-84 supplied pyridine N-oxide R-85
(Scheme 3A).
Several reference benzyl ethers (R-1,38 R-7,32 R-118, and R-
119) were sourced through direct alkylations of 6-R alcohol
5632 (Scheme 4A). Three extended ether targets (R-122, R-
123, and R-124) were also formed by Sonogashira reactions on
the propargyl ether R-121, derived from the coupling of 56
with bromide 120.41 Next, the orthogonally diprotected triol
12542 was employed in complementary syntheses of the novel
R and S enantiomers of racemic ether 642 (Scheme 4B,C).
Following a Mitsunobu reaction of 125 with 4-
(triﬂuoromethoxy)phenol, selective removal of the PMB
group (DDQ), iodination of the resulting alcohol 127, and
reaction with 2-bromo-4-nitroimidazole (129) gave silyl ether
130. Treatment of the latter with TBAF and sodium hydride-
induced ring closure then produced S-6. Conversely, successive
cleavage of the TIPS group from 126, iodination, and then
reaction with 129 provided PMB ether 134. Oxidative
debenzylation of 134 with DDQ in the absence of water
unexpectedly led to partial acetalization of the alcohol product
with 4-methoxybenzaldehyde, but this mixture was cleanly
converted back to 135 via acid hydrolysis (TsOH/MeOH).
Base-assisted annulation of alcohol 135 (NaH) then furnished
the second enantiomer, R-6. In subsequent work, 2-pyridinyl
ether analogues of both R-6 (R-136, R-137, and R-138) and
triazole 47 (139) were accessed from alcohols 5632 and 86,40
respectively, via sodium hydride-catalyzed SNAr displacement
reactions on halopyridines (Scheme 4D), while Cu(I)-induced
coupling of 56 with aryl isocyanates generated the O-
carbamates R-140 and R-141 (Scheme 4E). Finally, piperazine
carbamate R-143 was synthesized by chloroformylation of
alcohol 56 and in situ reaction with 1-[4-(triﬂuoromethoxy)-
phenyl]piperazine43 (142) (Scheme 4F).
Scheme 1a
aReagents and conditions: (i) 70−75 or 95 °C, 18−23 h; (ii) 3,4-dihydro-2H-pyran, PPTS, CH2Cl2, 20 °C, 3.5−24 h; (iii) TBAF, THF, 20 °C, 1−
4.5 h, or 0−20 °C, 14 h (for 47); (iv) MsOH, MeOH, 20 °C, 1−2 h; (v) 4-OCF3BnBr or 4-BnOBnCl or 4-BnOBnI, NaH, DMF, 20 °C for 3−20 h
or 0−20 °C for 0.7−2.2 h; (vi) TBSOTf, Et3N, CH2Cl2, 20 °C, 3 h; (vii) m-CPBA, CH2Cl2, 20 °C, 18 h; (viii) NaH, DMF, 20 °C for 18 h or 0−20
°C for 3.5 h; (ix) 3.3 M HCl, MeOH, 20 °C, 5 h; (x) DIPEA, toluene, 89−105 °C, 67 h.
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Further linker diversity was accessed through the trans-
formation of 6-S alcohol 6532 into the novel 6-R amine
hydrochloride, 146 (Scheme 5A). Following tosylation of 65
and azide displacement, reduction of 6-R azide 145 with
propane-1,3-dithiol gave the required amine, which was
converted to its hydrochloride salt for improved stability.
From this intermediate, reductive alkylation with benzalde-
hydes (using NaBH3CN), acylation with benzoyl chlorides, or
treatment with phenyl isocyanates in the presence of catalytic
dibutyltin diacetate yielded the expected benzylamine,
benzamide, or phenyl urea derivatives (Scheme 5A,B). Then,
to conclude this study, a variety of shorter O-linked
heterobiaryl side chains were constructed using Suzuki
couplings on haloheteroaryl ether precursors [156, 159, 167,
170, and 173 (Scheme 5C−E)]. The latter were obtained
directly from alcohol 56, via SNAr reactions on ﬂuoropyridines
or chloropyrimidines, or, in the case of 167, from the
diprotected triol 12542 and 6-bromopyridin-3-ol, using the
same methodology as described above for R-6.
■ RESULTS AND DISCUSSION
To establish the SARs against kinetoplastid diseases, 76 new
(and several known) pretomanid analogues derived from
successive projects with TB Alliance and DNDi were
retrospectively tested in replicate assays conducted at the
University of Antwerp [LMPH (Tables 1−4)]. These assays
measured activity versus the intracellular amastigote forms of
both Leishmania infantum (L. inf) and Trypanosoma cruzi (T.
cruzi) and against the bloodstream form of Trypanosoma brucei
(T. brucei); cytotoxicity toward human lung ﬁbroblasts (MRC-5
cells, the host for T. cruzi) was also assessed.44 Much of our VL
lead optimization work with DNDi was earlier guided by the
ﬁndings from single IC50 determinations against Leishmania
donovani (L. don) in a mouse macrophage-based luciferase
assay26 performed at the Central Drug Research Institute
(CDRI, Pradesh, India), and by follow-up evaluations of in vitro
microsomal stability and eﬃcacy in the mouse VL model
(Figure 2A). The best leads were then advanced to further
appraisal in the more stringent hamster VL model. Overall,
while excellent in vivo eﬃcacy was a key goal for second-
generation VL drug candidates, we also aspired (a) to minimize
compound lipophilicity (estimated using ACD LogP/LogD
software, version 14.04, Advanced Chemistry Development
Inc., Toronto, ON) to lessen toxicity risks, (b) to increase
aqueous solubility (as judged by kinetic data on dry powder
forms of active leads) for optimal oral bioavailability, and (c) to
reduce hERG inhibition potential (cf. 4)24 to improve safety.
Scaﬀold Modiﬁcation: Initial Hits. As part of our earlier
TB studies, we had examined some fundamental changes to the
nitroimidazooxazine “warhead”, including replacement of the
nitroimidazole ring by nitropyrazole or nitrotriazole [e.g., 48-50
(Table 1)] and exchange of the 8-oxygen for sulfur or
nitrogen.40 We had also explored reversal of the C-6 linker
(e.g., 24−26)29,30 and transposition of the side chain to
position 7 (e.g., 41 and 42).24 In a further extension to this
work (seeking improved metabolic stability and new active
Scheme 2a
aReagents and conditions: (i) NaH, DMF, 0−20 °C, 2.3−3.5 h; (ii) ArB(OH)2, DMF, (toluene, EtOH), 2 M Na2CO3 or 2 M KHCO3, Pd(dppf)Cl2
under N2, 70−88 °C, 2.2−4 h; (iii) NBS, PPh3, CH2Cl2, 20 °C, 3.5 h.
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scaﬀolds), the novel methylated derivatives 14, 22, and 23 were
investigated, together with nitroimidazooxazepines 32, 33, 39,
and 40. Unfortunately, except for the 7,7-dimethyl derivative 22
[which showed antitubercular potency comparable to that of 1
and excellent stability toward human liver microsomes, HLM,
92% after 1 h (Table 5)], these compounds proved to be
unattractive for TB. Nevertheless, in preliminary antiparasitic
screening at the Swiss Tropical Institute, 23, 25, and 26
demonstrated encouraging utility against L. don in a mouse
macrophage assay (IC50s of 1.2−1.5 μM),
29 and triazole 49
exhibited striking activity versus Chagas disease (T. cruzi IC50 of
0.084 μM). For greater clarity, we will focus the discussion ﬁrst
on the intended main application (VL) and discuss the other
parasite data in a closing section. Follow-up testing of a larger
set of compounds at CDRI26 identiﬁed 1, 6, 24, and 40 as being
superior for VL [L. don IC50s of 0.26−0.46 μM (Table 1)],
although such hits were still an order of magnitude less potent
than 4 and the 7-substituted oxazine 41 (IC50s of 0.03 μM).
24,25
These results, together with evidence of the reduced
solubility and more rapid metabolism of analogues with 4-
benzyloxybenzyl side chains,36,42 prompted the further appraisal
of 24 in an L. don infection VL mouse model. Disappointingly,
24 displayed weak activity [31% inhibition at 25 mg/kg, dosing
po daily for 5 days (Table 5)], despite its reasonable mouse PK
proﬁle [50% oral bioavailability, moderate exposure, and 2 h
half-life (Table 6)]. This outcome implied the need to
signiﬁcantly boost in vitro potencies in this class. However,
two highly eﬀective phenylpyridine analogues of 24, 11630 and
11730 [L. don IC50s of 0.02−0.05 μM (Table 2)], also failed to
deliver useful activity in this in vivo assay under the same dosing
regimen (23−49% inhibition). Analysis of their mouse PK data
identiﬁed low oral bioavailability (11−15%) as a contributing
factor here because greater oral exposure led to better eﬃcacy
[116 (Table 6 and Figure S1)]. A related concern for both
compounds was poor aqueous solubility [0.13−0.27 μg/mL at
pH 7 (Table 5)], while retrospective testing against L. inf later
revealed suboptimal potency (IC50s of ∼6 μM). Taken
together, these ﬁndings reinforced the importance of improving
both potency and in vivo PK properties, to achieve suitable
eﬃcacy in VL models. To this end, we returned to our sizable
pretomanid analogue library, where we had already amassed
key solubility and DMPK information from extensive earlier
studies with the TB Alliance.
Library Screening and Hit to Lead Assessments for
VL. To assist the identiﬁcation of more active leads from the 6-
substituted nitroimidazooxazine class, an 898-member library
was screened against L. don amastigotes in a seven-point 3-fold
dilution macrophage assay at the Institut Pasteur Korea (mid-
2010).45 In total, 248 compounds (28%) showed >50%
inhibition at 10 μg/mL, although only 89 (36%) of these
displayed >50% inhibition at 3.3 μg/mL, and known actives
from the nitroimidazooxazole and 7-substituted oxazine classes
were dispersed across both groupings. By eliminating examples
from previously inspected classes (including the “reversed C-6
linker” series above), we obtained a starting set of 169 hits. This
set was further reﬁned by excluding compounds with a higher
propensity for metabolic and/or solubility issues, based on
established trends, to give 42 hits, which were retested at CDRI.
Scheme 3a
aReagents and conditions: (i) NaH, DMF, 0−20 °C (or 0−8 °C), 2−2.7 h; (ii) ArB(OH)2, DMF, (toluene, EtOH), 2 M Na2CO3 or 2 M KHCO3,
Pd(dppf)Cl2 under N2, 80−89 °C for 2−4 h or 70 °C for 16 h; (iii) m-CPBA, Na2HPO4, CH2Cl2, 20 °C, 16 h.
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The most relevant results are summarized in Figure 3, with
almost all of the remaining hits manifesting weaker potencies
(L. don IC50s of 0.5−11 μM). We also screened S-1 and S-2,
but both had only modest activities (L. don IC50s of 3.9 and 2.6
μM, respectively). Nevertheless, in view of the 10-fold higher
potency of racemic 1 [IC50 of 0.39 μM (Table 1)], this result
for S-1 was highly signiﬁcant as it implied that 6R enantiomers
(which have little activity against M. tb32,37) may be the more
active chiral form for VL. Therefore, we synthesized a trial set
of 10 compounds (R-1, R-2, R-7, R-58, R-60, R-62, R-77, R-81,
R-84, and R-94) for assessment. In 9 of 10 cases, these 6R
enantiomers exhibited 1.1−12-fold superior potencies [L. don
IC50s of 0.06−1.4 μM (see Tables S2 and S3)]; hence, the 6R
counterparts of selected hits in Figure 3 were also targeted (in
line with the approach in Figure 2A).
In an eﬀort to further prioritize the library screening hits for
in vivo evaluation, ﬁve compounds of high lipophilicity (CLogP
> 4 for S-53,46 S-54,30 S-55,47 S-58,47 and S-6439) were omitted
from further study and the remaining 12 were assessed for
aqueous solubility and microsomal stability (Table 5 and cited
references for Figure 3). Both the amide S-15148 and urea S-
155 provided encouraging solubility data (132 and 22 μg/mL,
respectively), but the urea unexpectedly showed poor stability
toward mouse liver microsomes (MLM, 43% parent after 30
min). Conversely, both the lipophilic arylthiazole S-5149
(CLogP ∼ 4.0) and the arylpyrimidine S-17142 were considered
of borderline interest because of their modest solubility values
(0.9−1.6 μg/mL). While some phenylpyridine hits (e.g., S-77,
S-89, S-91, S-92, and S-99)39 were not substantially more
soluble than this at pH 7 (1.4−4.0 μg/mL), these compounds
have demonstrated greatly superior results at pH 1 (211−1780
μg/mL). It has been recognized that the low pH of gastric ﬂuid
(typically ∼1−2) can enhance the dissolution and oral
absorption of such weak bases.50 Furthermore, close analogue
S-2 was advanced to clinical studies for TB partly on the basis
of its superior in vivo PK properties in comparison to those of
delamanid (5), which are absorption-limited.23 Concordant
with this, the most potent phenylpyridine hits in Figure 3 (S-
77, S-81, S-89, S-91, and S-92) also displayed broadly
acceptable HLM and MLM stabilities (>70% remaining after
30 min), suggesting their suitability for in vivo studies.
The best six screening hits mentioned above (phenyl-
pyridines S-77, S-81, S-89, S-91, and S-92 and amide S-151)
were then evaluated in the mouse VL model alongside a similar
set of 6R enantiomers (R-77, R-84, R-89, R-91, R-92, R-94, and
R-151), dosing at 50 mg/kg orally, once daily for 5 days.
Results for the meta-linked phenylpyridines R-77, S-77, and S-
81 were not particularly impressive [52, 44, and 35% inhibition,
Scheme 4a
aReagents and conditions: (i) NaH, DMF, 0−20 °C, 0.25−5.5 h; (ii) TBAF, THF, 20 °C, 0.5−18 h; (iii) ArI or ArBr, Et3N, DMF, CuI,
Pd(PPh3)2Cl2 under N2, 70 °C for 0.25−1 h or 20 °C for 16 h; (iv) 4-OCF3PhOH, DEAD, PPh3, THF, 0−20 °C, 60 h; (v) DDQ, CH2Cl2, 20 °C,
10−28 h (then TsOH, MeOH, 20 °C, 12 h for 135); (vi) I2, PPh3, imidazole, CH2Cl2, 20 °C, 12−35 h; (vii) 128 or 133, K2CO3, DMF, 85−92 °C,
64−111 h; (viii) CuCl, DMF, 20 °C, 33−43 h; (ix) triphosgene, Et3N, THF, 0−20 °C, 1.7 h, then 142, THF, 20 °C, 3.5 h.
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respectively (Table 5)], although the level of activity did track
with their respective L. don IC50s (0.06, 0.12, and 0.24 μM,
respectively). In contrast, pairwise comparison of para-linked
phenylpyridines S-89, S-91, and S-92 with their 6R counterparts
unequivocally conﬁrmed the latter as being superior [R-89
(99.5%) vs S-89 (45%), R-91 (99.8%) vs S-91 (69%), and R-92
(94%) vs S-92 (37%)], notwithstanding their slightly higher
rates of metabolism (e.g., R-91, 81% parent after 30 min in
MLM, vs S-91, 100%). In this series, the 4-ﬂuoro analogue R-94
(L. don IC50 of 0.18 μM) showed reduced utility (83%),
whereas the apparently less potent 4-triﬂuoromethoxy congener
R-84 (IC50 of 0.32 μM in the same CDRI assay) provided
excellent eﬃcacy (99.4%), despite having lower microsomal
stability (36% vs 66% after 1 h in MLM). Overall, the most
eﬀective (6S) screening hit was the soluble amide S-151 (72%),
but its 6R form (R-151) was unexpectedly poor (5%).
However, for this 6-N-linked benzamide class, it was later
discovered that the 6S enantiomers had the stronger in vitro
potencies (e.g., L. inf IC50s of 5.6 and 12 μM for S-151 and R-
151, respectively), suggesting the need for a more systematic
investigation of the SAR (Figure 2B). For better clarity, we will
describe this analysis next, before summarizing the results from
additional in vivo assessments on all of the most active new VL
leads.
SAR of 6-Substituted 2-Nitroimidazooxazines for VL.
Following the discovery that many 6R enantiomers had
superior in vitro and in vivo activities against VL, a more
extensive lead optimization study was initiated to develop
additional backup candidates to 4 possessing an advantageous
solubility, PK−PD, and safety proﬁle. In light of the high
potency of ortho-linked biphenyl hit S-58 (L. don IC50 0.18
μM), we ﬁrst sought to establish the optimal linking position
for biaryl side chains. Comparison of R-58, R-60, and R-62 in
both L. don and L. inf assays (Table 2) unexpectedly indicated
that ortho linkage was most preferred and that para linkage was
least preferred. Therefore, the novel ortho-linked phenyl-
pyridines S-69, R-69, S-74, and R-74 were studied. Here, R-
69 and R-74 were equally best, although 1.8-fold less eﬀective
than R-58 (L. inf IC50s of 2.0 vs 1.1 μM). Interestingly, these
two phenylpyridine isomers showed major diﬀerences in both
solubility and microsomal stability, with the more soluble R-74
(78 vs 0.51 μg/mL) being metabolized extremely rapidly in all
three microsome species [0.1−8% remaining after 1 h (Table
5)], whereas R-69 was more stable than the para-linked
analogue R-84 described above (44% vs 36% after 1 h in
MLM).
In the meta-linked phenylpyridine series, two new com-
pounds (R-79 and R-80) having terminal ring substituents
Scheme 5a
aReagents and conditions: (i) TsCl, pyridine, 49 °C, 17 h; (ii) NaN3, DMSO, 64 °C, 3.5 days; (iii) HS(CH2)3SH, Et3N, MeOH, 20 °C, 0.5 h, then
HCl, dioxane; (iv) NaBH3CN, AcOH, DMF, 0−20 °C, 7−20 h; (v) DIPEA, DMF, 20 °C, 10−25 h; (vi) NMM or DIPEA, Bu2Sn(OAc)2, DMF, 20
°C, 4−18 h; (vii) NaH, DMF, 0−20 °C, 2.7−3.4 h; (viii) ArB(OH)2, DMF, toluene, EtOH, 2 M Na2CO3, Pd(dppf)Cl2 under N2, 84−89 °C, 1.3−
3.5 h; (ix) 6-bromopyridin-3-ol, DEAD, PPh3, THF, 0−20 °C, 89 h; (x) TBAF, THF, 20 °C, 13 h; (xi) I2, PPh3, imidazole, CH2Cl2, 20 °C, 41 h;
(xii) 164, K2CO3, DMF, 88 °C, 122 h; (xiii) DDQ, CH2Cl2, 20 °C, 98 h, then TsOH, MeOH, CH2Cl2, 20 °C, 10 h.
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favored in para-linked isomers described above (2-F, 4-OCF3,
and 4-OCF2H) were marginally more potent than R-77 (4-
OCF3) and R-81 (4-F) [L. inf IC50s of 0.45 and 0.51 vs 0.63
and 0.73 μM, respectively (Table 2)]. Here, replacement of the
proximal phenyl ring in R-60 by 2-pyridine (R-77) resulted in a
3.7-fold improvement in activity (L. inf IC50s of 2.3 and 0.63
μM). This enhancement by 2-pyridine was even more
pronounced in the para-linked phenylpyridine series (L. inf
IC50s of 0.71 and >64 μM for R-84 and R-62, respectively),
clarifying that with this heterocycle, ortho linkage was less useful
than meta or para linkage. However, in the para-linked set, we
considered that the 2′-nitrogen would have less steric
protection against oxidation, perhaps accounting for the modest
microsomal stabilities of some analogues. Indeed, we could
form the N-oxide derivative of R-84 (R-85), which was found
to be 2.3-fold less potent (L. inf IC50 of 1.6 μM). Because
microsomal stability varied signiﬁcantly with the substituents in
the terminal ring, we evaluated three new congeners (R-90, 3-F,
4-OCF3; R-93, 4-CF3; R-96, 2,4-diF). The most promising of
these was R-96 (L. inf IC50 of 1.2 μM, activity ∼2-fold weaker
than those of early leads R-84, R-89, R-91, and R-92), which
exhibited a better stability proﬁle in MLM and HLM [57−59%
vs 16−40% for R-84, R-89, and R-91 (Table 5)].
As suggested by the screening data (Figure 3), replacement
of the proximal phenyl ring in R-62 with 3-pyridine (R-2) was
less favorable [L. inf IC50 of 4.1 μM vs 0.71 μM for R-84 (Table
2)]. Nevertheless, the 6R enantiomers of two hits (R-99, 2-F, 4-
OCF3; R-101, 2-Cl, 4-OCF3) and the novel 2,4-diﬂuoro
analogue R-106 all displayed good potencies (L. inf IC50s of
1.1, 0.61, and 0.85 μM, respectively) and microsomal stabilities
at least comparable to those of their 2-pyridine counterparts,
although R-101 was cytotoxic (MRC-5 IC50 of 17 μM). By
extension, we examined three less lipophilic diaza proximal
rings (R-109, R-112, and R-115) that had proven to be very
eﬀective in our TB studies,39 but these turned out to be of less
interest (L. inf IC50s of 1.4−2.8 μM). In summary, several new
phenylpyridines provided proﬁles that were attractive for in vivo
evaluation, but we had yet to investigate other linker groups.
Therefore, we next turned our attention to simpler monoaryl
side chains to explore these changes. For this part of the study,
we restricted our focus to linkers that had shown particular
promise either in the initial screening (e.g., 6-O, 6-NHCO, and
6-NHCONH) or in our earlier TB work.
Commencing with the enantiomer of pretomanid [R-1, L. inf
IC50 of 4.7 μM (Table 3)], we found variation of the
triﬂuoromethoxy position identiﬁed that ortho substitution was
Table 1. In Vitro Antiparasitic and Antitubercular Activities for Racemic Nitroheterobicyclic Scaﬀold Variants
IC50
a,b (μM) MICb,c (μM)
compd form R CLogP L. don L. inf T. cruzi T. brucei MRC-5 MABA LORA
6d Aa OCF3 2.48 0.39 0.95 0.39 >64 >64 2.9 9.6
1e Ab OCF3 2.70 0.39 4.0 1.2 >64 >64 1.1 4.4
7e Ab OBn 3.32 1.1 5.9 0.38 >64 >64 0.11 2.7
14 Bb OCF3 3.24 78 >64 50 >64 >64 7.4 55
22 Cb OCF3 3.74 5.5 2.2 0.53 34 >64 1.2 9.6
23 Cb OBn 4.36 0.77 2.5 0.27 29 >64 2.2 8.3
24f Da OCF3 2.78 0.46 4.0 <0.13 >64 >64 0.63 16
25f Db OCF3 2.77 2.6 1.7 <0.13 >64 >64 2.4 7.9
26f Db OBn 3.39 2.0 2.6 <0.13 >64 >64 3.1 35
32 Eb OCF3 2.74 >2 >64 51 >64 >64 >128 >128
33 Eb OBn 3.36 >2 16 2.3 23 >64 >128 >128
39 Fb OCF3 2.74 0.63 >64 4.2 >64 58 52 35
40 Fb OBn 3.36 0.26 >64 2.3 3.2 >64 >128 86
41g Gb OCF3 2.88 0.03 0.12 1.2 >64 >64 1.0 7.5
42g Gb OBn 3.50 0.05 0.46 3.0
47 Ha OCF3 2.51 >64 1.3 >64 >64
48e Hb OCF3 2.74 >64 0.73 38 >64 >128 >128
49e Hb OBn 3.36 >64 0.25 >64 >64 >128 >128
50e Ib OCF3 3.26 >64 8.2 46 >64 >128 >128
aIC50 values for inhibition of the growth of L. don and L. inf (in mouse macrophages), T. cruzi (on MRC-5 cells), and T. brucei, or for cytotoxicity
toward human lung ﬁbroblasts (MRC-5 cells). bEach value (except the single-test L. don data) is the mean of at least two independent
determinations. For complete results (mean ± SD), see the Supporting Information. cMinimum inhibitory concentration against M. tb, determined
under aerobic (MABA)59 or hypoxic (LORA)60 conditions. dTB data from ref 42. eTB data from ref 40. fTB data from ref 30. gData from ref 24.
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Table 2. In Vitro Antiparasitic Activities of 6-OCH2/CH2O-Linked Biaryl Nitroimidazooxazines
IC50
a,b (μM)
compd form link aza R CLogP L. don L. inf T. cruzi T. brucei MRC-5
S-51c 3.97 0.25 2.3 4.2 >64 >64
S-52c 2.60 0.40 5.2 4.9 >64 >64
S-58d A 2′ 4-OCF3 4.36 0.18 30 0.88 >64 >64
R-58 B 2′ 4-OCF3 4.36 0.17 1.1 0.64 >64 >64
R-60 B 3′ 4-OCF3 4.36 0.31 2.3 0.43 22 62
R-62 B 4′ 4-OCF3 4.36 1.2 >64 0.12 >64 >64
S-64e A 4′ 2 4-CF3, 6-Cl 4.46 0.13 1.5 3.3 54 >64
R-64 B 4′ 2 4-CF3, 6-Cl 4.46 0.21 0.87 0.65 43 57
S-69 A 2′ 3′ 4-OCF3 3.01 28 >64 6.7 >64 >64
R-69 B 2′ 3′ 4-OCF3 3.01 0.78 2.0 1.9 >64 >64
S-74 A 2′ 6′ 4-OCF3 3.04 4.8 9.1 6.3 >64 >64
R-74 B 2′ 6′ 4-OCF3 3.04 0.86 2.0 1.3 18 >64
S-77e A 3′ 2′ 4-OCF3 3.01 0.12 1.9 2.0 >64 47
R-77 B 3′ 2′ 4-OCF3 3.01 0.06 0.63 0.25 46 61
S-79 A 3′ 2′ 2-F, 4-OCF3 3.57 2.4 3.8 >64 >64
R-79 B 3′ 2′ 2-F, 4-OCF3 3.57 0.45 0.56 >64 >64
R-80 B 3′ 2′ 4-OCF2H 2.16 0.51 0.26 >64 >64
S-81e A 3′ 2′ 4-F 2.10 0.24 32 3.9 >64 >64
R-81 B 3′ 2′ 4-F 2.10 0.12 0.73 0.36 >64 >64
S-84e A 4′ 2′ 4-OCF3 3.04 0.83 10 1.4 43 >64
R-84 B 4′ 2′ 4-OCF3 3.04 (0.24)f 0.71 0.043 >64 >64
S-85g A 4′ 2′-Oh 4-OCF3 0.94 9.1 5.4 11 >64
R-85 B 4′ 2′-Oh 4-OCF3 0.94 1.6 3.3 >64 >64
88i 3.08 41 0.52 3.5 14
S-89e A 4′ 2′ 2-F, 4-OCF3 3.60 0.18 14 1.8 >64 >64
R-89 B 4′ 2′ 2-F, 4-OCF3 3.60 (0.27)f 0.62 0.078 >64 >64
R-90 B 4′ 2′ 3-F, 4-OCF3 3.02 3.5 0.025 >64 >64
S-91e A 4′ 2′ 2-Cl, 4-OCF3 3.75 0.16 2.4 2.5 35 20
R-91 B 4′ 2′ 2-Cl, 4-OCF3 3.75 (0.31)f 0.57 0.12 35 41
S-92e A 4′ 2′ 4-OCF2H 2.19 0.08 3.4 1.2 46 >64
R-92 B 4′ 2′ 4-OCF2H 2.19 0.86 0.63 0.078 >64 >64
R-93 B 4′ 2′ 4-CF3 3.17 6.1 0.072 >64 >64
R-94 B 4′ 2′ 4-F 2.13 0.18 2.3 0.16 >64 >64
S-96 A 4′ 2′ 2,4-diF 2.67 1.4 7.8 >64 >64
R-96 B 4′ 2′ 2,4-diF 2.67 (0.39)f 1.2 0.23 55 >64
R-2 B 4′ 3′ 4-OCF3 3.01 1.4 4.1 0.27 >64 >64
S-99e A 4′ 3′ 2-F, 4-OCF3 3.57 0.33 >64 1.4 >64 >64
R-99 B 4′ 3′ 2-F, 4-OCF3 3.57 (0.48)f 1.1 0.19 >64 >64
R-100 B 4′ 3′ 3-F, 4-OCF3 2.99 12 0.24 >64 >64
S-101e A 4′ 3′ 2-Cl, 4-OCF3 3.72 0.34 5.2 2.4 23 20
R-101 B 4′ 3′ 2-Cl, 4-OCF3 3.72 0.61 0.15 34 17
R-102 B 4′ 3′ 4-OCF2H 2.16 1.9 0.56 >64 >64
R-103 B 4′ 3′ 4-CF3 3.14 11 0.64 >64 >64
R-104 B 4′ 3′ 4-F 2.10 1.9 1.7 >64 >64
S-106 A 4′ 3′ 2,4-diF 2.64 5.3 51 >64 >64
R-106 B 4′ 3′ 2,4-diF 2.64 (0.64)f 0.85 1.3 >64 >64
R-109 B 4′ 2′,3′ 4-OCF3 1.52 2.3 0.55 >64 >64
R-112 B 4′ 2′,5′ 4-OCF3 2.19 2.8 0.27 >64 >64
R-115 B 4′ 2′,6′ 4-OCF3 2.63 1.4 0.28 >64 >64
116g C 4′ 3′ 4-OCF3 3.38 0.05 6.1 <0.13 0.63 >64
117g C 4′ 3′ 4-F 2.46 0.02 6.3 <0.13 17 >64
aIC50 values for inhibition of the growth of L. don and L. inf (in mouse macrophages), T. cruzi (on MRC-5 cells), and T. brucei, or for cytotoxicity
toward human lung ﬁbroblasts (MRC-5 cells). bEach value (except the single-test L. don data) is the mean of at least two independent
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best (R-119, L. inf IC50 of 1.4 μM), followed by meta
substitution (R-118), mimicking ﬁndings for biphenyl linkage.
Switching to a propargyl ether42 (R-122) produced much
greater activity (L. inf IC50 of 0.33 μM), which was largely
retained in triﬂuoromethylpyridine replacements for the aryl
ring25 (L. inf IC50s of 0.44 and 0.53 μM for R-123 and R-124,
respectively). Conversely, removal of the benzylic methylene
(R-6) also enabled high potency (L. inf IC50 of 0.53 μM, L. don
IC50 of 0.19 μM), while critically allowing the retention of good
aqueous solubility (12 μg/mL) and high microsomal stability
[79−81% parent after 1 h in MLM and HLM (Table 5)].
Therefore, we similarly investigated triﬂuoromethylpyridine
analogues of R-6 (R-136, R-137, and R-138) and while there
was an ∼2-fold loss of activity, R-136 demonstrated a 9-fold
Table 2. continued
determinations. For complete results (mean ± SD), see the Supporting Information. cFrom ref 49. dFrom ref 47. eFrom ref 39. fLMPH data (mean
of three or four values). gFrom ref 30. hN-Oxide. iRacemic nitrotriazolooxazine analogue of R-84.
Table 3. In Vitro Antiparasitic Activities of Variously Linked Monoaryl Nitroimidazooxazines
IC50
a,b (μM)
compd form X aza R CLogP L. don L. inf T. cruzi T. brucei MRC-5
S-1c A OCH2 4-OCF3 2.70 3.9 59 10 >64 >64
R-1d B OCH2 4-OCF3 2.70 0.54 4.7 0.40 >64 >64
R-118 B OCH2 3-OCF3 2.70 2.5 0.31 >64 >64
R-119 B OCH2 2-OCF3 2.70 1.4 0.20 >64 >64
S-48e C OCH2 4-OCF3 2.74 >64 0.74 >64 >64
R-48e D OCH2 4-OCF3 2.74 >64 0.54 >64 >64
S-7c A OCH2 4-OBn 3.32 1.7 >64 51 >64 >64
R-7c B OCH2 4-OBn 3.32 0.14 0.87 0.39 >64 >64
R-122 B OCH2CC 4-OCF3 3.94 0.33 0.11 >64 >64
R-123 B OCH2CC 2 4-CF3 2.47 0.44 1.4 21 28
R-124 B OCH2CC 3 4-CF3 2.47 0.53 1.2 >64 >64
S-6 A O 4-OCF3 2.48 8.2 7.3 >64 >64
R-6 B O 4-OCF3 2.48 (0.19)
f 0.53 0.15 >64 >64
R-136 B O 2 4-CF3 2.33 (0.15)
f 1.1 0.34 25 >64
R-137 B O 2 3-CF3 2.13 1.2 0.35 >64 >64
R-138 B O 2 5-CF3 1.73 0.85 2.4 23 >64
139g 2.37 >64 23 >64 >64
R-24h A CH2O 4-OCF3 2.78 0.13 0.86 0.33 57 >64
S-24h B CH2O 4-OCF3 2.78 0.11 2.2 <0.13 >64 >64
S-140c A OCONH 4-OCF3 2.11 3.3 7.3 6.8 >64 >64
R-140 B OCONH 4-OCF3 2.11 2.1 3.5 48 >64
R-141 B OCONH 2-OCF3 2.51 6.4 1.5 >64 >64
S-143i A OCOpipj 4-OCF3 1.56 0.88 14 2.1 >64 >64
R-143 B OCOpipj 4-OCF3 1.56 17 0.27 >64 >64
S-147i A NHCH2 4-OCF3 2.26 6.1 >64 11 3.6 >64
R-147 B NHCH2 4-OCF3 2.26 12 1.8 3.3 >64
R-148 B NHCH2 3-OCF3 2.26 6.9 <0.13 2.0 >64
R-149 B NHCH2 2-OCF3 2.26 8.6 0.15 2.1 >64
S-150c A NHCO 4-OCF3 1.75 6.0 19 >64 >64
R-150 B NHCO 4-OCF3 1.75 57 2.5 >64 >64
S-151i A NHCO 3-OCF3 1.22 0.25 5.6 25 >64 >64
R-151 B NHCO 3-OCF3 1.22 12 0.87 >64 >64
S-152i A NHCO 2-OCF3 1.40 5.8 53 >64 >64
R-152 B NHCO 2-OCF3 1.40 18 0.96 >64 >64
S-154c A NHCONH 4-OCF3 1.47 10 7.5 22 >64
R-154 B NHCONH 4-OCF3 1.47 >64 2.3 19 >64
S-155 A NHCONH 2-OCF3 1.73 0.23 6.8 3.1 4.9 16
R-155 B NHCONH 2-OCF3 1.73 55 1.3 >64 48
aIC50 values for inhibition of the growth of L. don and L. inf (in mouse macrophages), T. cruzi (on MRC-5 cells), and T. brucei, or for cytotoxicity
toward human lung ﬁbroblasts (MRC-5 cells). bEach value (except the single-test L. don data) is the mean of at least two independent
determinations. For complete results (mean ± SD), see the Supporting Information. cFrom ref 32. dFrom ref 38. eFrom ref 40. fLMPH data (mean
of three values). gRacemic nitrotriazolooxazine analogue of R-136. hFrom ref 30. iFrom ref 48. jN-Piperazine.
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improvement in aqueous solubility (110 μg/mL), together with
a slower rate of metabolism (90−92% parent after 1 h in MLM
and HLM). However, changing to an O-carbamate linker48 (R-
140, R-141, and R-143) proved to be less satisfactory, with
moderate to low potencies observed (L. inf IC50s of 2.1−17
μM).
Another option to improve solubility was to replace the ether
linkage at C-6 with nitrogen-based linkers.48 The 6-amino
analogue of R-1 (R-147) had a 5-fold better solubility value at
pH 7 (84 μg/mL) and was >2000 times more soluble at pH 1.
Nevertheless, this compound was less stable toward micro-
somes (e.g., 61% vs 86% in MLM) and showed 2.6-fold lower
activity (L. inf IC50 of 12 vs 4.7 μM), which was not suﬃciently
improved by varying the ring substituent position (R-148 and
R-149). Alternatively, with a carboxamide or urea linker, the
enantiomer preference was reversed, with the original 6S forms
(S-150, S-151, S-152, S-154, and S-155) being clearly superior
but not particularly potent (L. inf IC50s of ∼6−10 μM). Hence,
the only compounds with useful antileishmanial activity were
ether-linked at C-6, although it was apparent that the original
OCH2 linkage was not optimal and that removal of the benzylic
methylene may have metabolic stability and potency advan-
tages. To investigate this further, a small set of O-linked
phenylpyridine and phenylpyrimidine derivatives was evaluated
(Table 4). In the phenylpyridine series (R-157 to R-169),
activity against L. inf was similar to or better than that for R-6,
with the 3-pyridine isomers preferred (R-168 and R-169, IC50s
of 0.13−0.20 μM). These latter compounds exhibited micro-
somal stabilities comparable to those of the parent linker series
above, but their solubility values were inferior (0.36−1.2 μg/
mL at pH 7). Finally, contrary to the screening data for S-171, a
proximal pyrimidine ring was tolerated only when it was para-
linked (R-174 and R-175, L. inf IC50s of 0.65−0.83 μM).
Generally, potency against L. inf was more discriminating and
tended to better correlate with in vivo outcomes.24,25
Throughout the course of these studies, 10 more candidates
(R-1, R-6, R-69, R-96, R-99, R-106, R-136, R-147, R-168, and
R-169) were screened for activity in the mouse VL model at 50
mg/kg [dosing po daily for 5 d (Table 5)]. The ortho-linked
phenylpyridine R-69 was disappointing (20% inhibition), but
the new para-linked analogues R-96, R-99, and R-106 displayed
high eﬃcacies (91−97%). More heartening still was the fact
that shorter chain phenylpyridines R-168 and R-169 gave
essentially complete clearance of the parasite infection (99.9%),
as did their monoaryl counterparts, R-6 and R-136. However,
both R-1 and its amino-linked equivalent R-147 were
unsatisfactory (50 and 12%, respectively), consistent with
their weaker in vitro potencies. During the concluding stages of
this project, Patterson et al.38 reported that R-1 was a potential
oral treatment for VL on the basis of its in vivo activity in a
comparable mouse model at a much larger dose of 100 mg/kg
twice daily, but it is clear from these results and other studies24
that R-1 may not be the optimal development candidate.
Additional Assessments To Determine the Best VL
Lead. Dose−response experiments on 7 of the 10 best
compounds (R-6, R-84, R-89, R-91, R-92, R-96, and R-99) in
the mouse VL model yielded ED50 values of 7.5, 12, 14, 28, 20,
28, and 19 mg/kg, respectively (Table 5 and Figure 4). The
more recent O-linked leads, R-136, R-168, and R-169, were
also evaluated at a smaller dose of 6.25 mg/kg and provided
parasite burden reductions of 30, 99.7, and 72%, respectively.
The most eﬃcacious of these (R-168) produced 84% inhibition
at 3.13 mg/kg, representing activity at a level similar to that of
Table 4. In Vitro Antiparasitic Activities of 6-O-Linked Biaryl Nitroimidazooxazines
IC50
a,b (μM)
compd form link aza R CLogP L. don L. inf T. cruzi T. brucei MRC-5
R-157 B 3′ 2′ 4-OCF3 3.27 0.31 <0.13 7.5 >64
R-158 B 3′ 2′ 4-F 2.35 0.41 0.30 >64 >64
R-160 B 4′ 2′ 4-OCF3 3.35 0.64 0.11 9.3 42
R-161 B 4′ 2′ 4-F 2.43 0.43 <0.13 10 >64
R-168 B 4′ 3′ 4-OCF3 3.07 0.13 0.15 >64 >64
R-169 B 4′ 3′ 4-F 2.15 0.20 0.40 >64 >64
S-171c A 3′ 4′,6′ 4-OCF3 2.79 0.10 23 2.0 >64 47
R-171 B 3′ 4′,6′ 4-OCF3 2.79 21 <0.13 >64 >64
R-172 B 3′ 4′,6′ 4-F 1.87 49 0.68 >64 >64
R-174 B 4′ 2′,6′ 4-OCF3 2.71 0.65 0.48 >64 >64
R-175 B 4′ 2′,6′ 4-F 1.80 0.83 0.64 >64 >64
aIC50 values for inhibition of the growth of L. don and L. inf (in mouse macrophages), T. cruzi (on MRC-5 cells), and T. brucei, or for cytotoxicity
toward human lung ﬁbroblasts (MRC-5 cells). bEach value (except the single-test L. don data) is the mean of at least two independent
determinations. For complete results (mean ± SD), see the Supporting Information. cFrom ref 42.
Figure 2. Schematic diagram of the two lead optimization approaches
(A and B) employed.
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the nitroimidazooxazole 4,25,26 albeit marginal aqueous
solubility (0.85 μM at pH 7) deterred its advanced assessment.
Instead, we elected to focus initially on the monoaryl ethers R-6
and R-136, together with phenylpyridines R-84 and R-89,
which all produced favorable mouse PK data, including
excellent oral exposure levels and half-lives of 6−30 h (Table
6 and Figure S1).
The selected candidates were further assessed in the chronic
infection hamster model, which is considered the bona ﬁde
experimental model for VL because it mimics many features of
progressive human disease.51 Pleasingly, at 50 mg/kg twice
daily for 5 days, phenylpyridine R-84 achieved 99.9−100% L.
inf clearance in all three target organs, and R-89 was almost as
good (Table 7 and Figure 5), although both compounds were
less inhibitory in bone marrow at 25 mg/kg b.i.d. (81−88%).
The monoaryl ethers R-6 and R-136 were even more eﬀective
at both dose levels, enabling a 97−99% parasite kill at 25 mg/kg
b.i.d. (for comparison, this eﬃcacy level was similar to that
observed for 3 at 12.5 mg/kg b.i.d.24). Pyridinyl ether R-136
additionally demonstrated fully curative activity (100% parasite
clearance in all three organs) at 25 mg/kg b.i.d. in an L. don
infection hamster model. Three more phenylpyridines (R-96,
R-99, and R-106) were similarly evaluated in the L. inf hamster
model, but only R-99 (the 3-pyridyl isomer of R-89) showed
any promise (86−98% at 50 mg/kg b.i.d.), paralleling eﬃcacy
trends in the mouse model. These results were also broadly in
line with the hamster PK data, where R-96 and R-106 displayed
inferior oral exposures and oral bioavailabilities (21−37%)
much lower than those of the other leads [64−100% (Table 6
and Figure S2)].
To better discriminate among the four preferred candidates,
we next considered key safety features, starting with measuring
their interactions with the hERG channel. While the monoaryl
ethers R-6 and R-136 posed minimal risk (hERG IC50s of >30
μM), unfortunately, phenylpyridines R-84 and R-89 both
caused potent inhibition (IC50s of 0.81 and 0.92 μM,
respectively), indicating a strong likelihood of QT prolonga-
tion52 (lead optimization criteria53,54 mandate an IC50 of >10
μM). This outcome was not anticipated, as 6S counterparts had
generated much less concern. The two remaining compounds
Table 5. Aqueous Solubility, Microsomal Stability, and in Vivo (mouse) Antileishmanial Eﬃcacy Data for Selected Analogues
aqueous solubilitya (μg/mL) microsomal stabilityb [% remaining at 1 (0.5) h] in vivo eﬃcacy against L. don (% inhibition at dose in mg/kg)c
compd pH 7 pH 1 H M Ham 50 25 12.5 6.25 ED50
d
S-1 19 82 94
R-1 18 92 86 31 50
R-6 12 81 79 19 >99 >99 81 42 7.5
22 6.0 92 72
24 3.9 (78) (88) (70) 31
S-51 1.6 (78) (75) (43)
S-52 2.7 87 67
R-69 0.51 263 35 44 3.0 20
R-74 78 7350 8.0 0.2 0.1
S-77 3.0 211 (75) (78) (31) 44
R-77 1.5 167 (68) (68) (31) 52
S-81 15 439 (96) (74) (15) 35
R-81 6.0 691 (79) (68) (0)
R-84 3.0 1040 27 (66) 36 (70) 10 (61) >99 76 42 36 12
S-89 1.4 479 (88) (84) (69) 45
R-89 3.4 503 27 (75) 40 (79) 10 (69) >99 72 48 17 14
S-91 1.4 384 (73) (100) (75) 69
R-91 2.9 12 16 (65) 27 (81) 5.8 (57) >99 38 6 28
S-92 4.0 1780 (92) (88) (59) 37
R-92 5.7 2050 49 (71) 56 (86) 11 (45) 94 54 20 20
R-94 11 4600 58 (85) 66 (77) 10 (37) 83
R-96 40 7140 59 57 5.2 97 48 29 17 28
R-99 2.9 364 37 41 9.2 97 64 31 8 19
R-102 2.1 857 58 56 7.9
R-106 3.9 925 58 67 10 91
116 0.13 32 (88) (96) (88) 49
117 0.27 132 (85) (66) (64) 23
R-136 110 90 92 48 >99 30
R-147 84 38100 84 61 7.5 12
S-151 132 (100) (83) (81) 72
R-151 85 87 86 59 5
S-155 22 (74) (43) (64)
R-168 0.36 36 40 35 >99 >99 <3.1
R-169 1.2 325 73 59 >99 72
aKinetic solubility in water (pH 7) or 0.1 M HCl (pH 1) at 20 °C, determined by HPLC (see Method A in Experimental Section). bPooled human
(H), CD-1 mouse (M), or hamster (Ham) liver microsomes; data in parentheses are the percentage parent compound remaining following a 30 min
incubation. cDosing was done orally, once daily for 5 days consecutively; data are the mean percentage reduction of parasite burden in the liver.
dDose in milligrams per kilogram required to achieve a mean 50% reduction in parasite burden.
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Table 6. Pharmacokinetic Parameters for Selected Compounds in Mice, Rats, and Hamsters
intravenous (1−2 mg/kg)a oral (25−50 mg/kg)a
compd C0 (μg/mL) CL (mL/min/kg) Vdss (L/kg) t1/2 (h) AUClast
b (μg·h/mL) Cmax (μg/mL) Tmax (h) t1/2 (h) AUClast
b (μg·h/mL) Fc (%)
Mice
R-6 21 5.3 7.8 272
24 0.34 13 2.5 2.0 1.25 1.5 1.0 15.7 50
R-84 16 4.7 9.4 211
R-89 32 3.3 6.1 265
116 0.75 1.2 1.9 20 11.7 0.87 10 32.2 11
117 0.44 5.2 1.8 2.7 3.18 0.84 8.0 12.0 15
R-136 96 3.1 30 1777
Rats
R-6 0.54 11 2.7 3.0 1.51 5.2 6.7 -d 80.6 100
R-136 0.84 6.1 1.5 2.7 2.47 18 2.7 3.5 164 100
Hamsters
R-6 0.66 81 6.5 1.4 0.42 2.1 3.3 2.2 11.2 100
R-84 0.65 23 8.2 6.3 1.30 5.7 3.0 5.8 62.7 100
R-89 0.94 18 4.2 3.9 1.89 4.2 2.0 3.9 26.7 74
R-96 0.93 63 4.0 0.83 0.48 1.9 0.75 0.83 3.95 37
R-99 1.1 8.8 3.2 5.3 3.69 4.7 3.3 5.8 46.5 64
R-106 0.52 59 5.4 1.4 0.71 1.1 1.7 17 3.40 21
R-136 12 3.3 3.1 71.0
aThe intravenous dose was 1 mg/kg for mice and rats and 2 mg/kg for hamsters. The oral dose was 25 mg/kg for 24, 116, and 117, 50 mg/kg for R-
106 and R-136, and 40 mg/kg for the other compounds. bArea under the curve calculated to the last time point (24 or 48 h). cOral bioavailability,
determined using dose-normalized AUClast values.
dNot calculable.
Figure 3. Potencies of 17 selected phenotypic screening hits30,39,42,46−49 against L. don (percent inhibition data from IPK, IC50s from CDRI).
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01581
J. Med. Chem. XXXX, XXX, XXX−XXX
M
were then checked for any evidence of mutagenicity in the
Ames test. Here, phenyl ether R-6 was negative, but the more
soluble pyridinyl ether R-136 unexpectedly yielded a positive
result. Although several other nitroimidazole drugs are Ames
positive (e.g., metronidazole and fexinidazole),55 this outcome
eﬀectively ruled R-136 out of contention because it would face
a more diﬃcult path to achieving regulatory approval.16,53 Thus,
R-6 was identiﬁed as the optimal VL lead.
Further Appraisal of VL lead R-6. Additional properties
of R-6 were measured and weighed against those of the initial
preclinical candidate 4 (Table 8). The two compounds were
comparable in terms of molecular weight (345 Da vs 359 Da)
and were both highly permeable, but R-6 had a lower measured
LogD value (2.59 vs 3.10 for 4 and 2.52 for S-148), superior
thermodynamic solubility (23 μM vs 2.8 μM), and a reduced
propensity to bind to plasma proteins in various species (82−
87% vs 92−96% for 4). This lead also showed only weak
CYP3A4 activity (IC50 > 40 μM) and produced a notably
favorable rat PK proﬁle, with prolonged exposure and 100%
oral bioavailability (Table 6 and Figure S2). These attributes
reinforced our conclusion that R-6 (DNDI-8219) was indeed a
very promising backup candidate for VL.
A larger scale synthesis of R-6 has recently provided a single
170 g batch of high-quality material (HPLC purity of >99.9%
and 97.2% ee) in reasonable overall yield (8% over nine linear
Figure 4. Comparative in vivo eﬃcacy in the L. don mouse model: (a) 25 mg/kg and (b) 6.25 mg/kg. All compounds except racemates 24, 116, and
117 are the 6R form.
Table 7. In Vivo Eﬃcacy Data for Selected Compounds in
the Early Curative L. inf Hamster Model
% inhibition in target organsb
compd dosea (mg/kg) liver spleen bone marrow
MIL 40 99.0 99.5 96.8
R-6 50 100 100 99.8
25 98.4 99.2 97.0
12.5 53.5 47.6 37.3
R-84 50 100 99.9 99.9
25 98.1 98.4 88.3
12.5 69.6 55.7 33.6
R-89 50 99.9 99.9 98.9
25 99.1 93.7 81.3
12.5 83.5 70.6 50.4
R-96 50 73.0 55.1 55.7
R-99 50 97.7 97.5 86.0
R-106 50 55.7 17.6 45.0
R-136 50 100 100 99.9
25 99.5 97.3 97.7
12.5 44.4 43.0 53.0
aAll test compounds were dosed orally, twice daily for 5 days
consecutively; miltefosine (MIL) was dosed once daily for the same
period. bData are the mean percentage reductions in parasite burden
in target organs.
Figure 5. Comparative in vivo eﬃcacy in the L. inf hamster model. All compounds are the 6R form.
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steps, starting from commercial R-solketal). However, the
current synthetic route would still require signiﬁcant improve-
ment to deliver a scalable, robust, and cost-eﬀective chemical
process, in line with the stated TPP objectives for an aﬀordable
drug. Possible alternatives include using the known56
enantiomer of orthogonally diprotected triol 125 and following
the pathway described for S-6 in Scheme 4B because this
enantiomer could be obtained from the cheap, optically pure
starting material D-mannitol (via the less expensive S-
solketal).57
Mechanistic studies of the closely related nitroimidazoox-
azine R-1 demonstrated that it was not activated by the
previously identiﬁed type I nitroreductase (NTR1) in
Leishmania, which mediates the cidal eﬀects of monocyclic
nitroheterocyclic drugs such as fexinidazole and nifurtimox.38,58
Instead, the activity of R-1 was solely triggered by the same
novel ﬂavin mononucleotide-dependent NADH oxidoreductase
(NTR2) in Leishmania that was employed by nitroimidazoox-
azoles, such as 4 and 5.27 This new mode of action was
elucidated through a combination of quantitative proteomics
and whole genome sequencing of susceptible and drug resistant
L. don promastigotes, the latter being generated via culture in
the continuous presence of R-1 for 80 days (leading to a
reduced level of expression of NTR2).27 The further
observation that R-1 and fexinidazole sulfone displayed additive
eﬀects against drug susceptible L. don sparked the suggestion of
combination therapy between monocyclic and bicyclic nitro
drugs to reduce the likelihood of any future clinical drug
resistance.38 However, we consider that it may be more
preferable to look for alternative partner drugs for 3 (or R-6)
with greater diversity in their mechanism of action.
One ﬁnal aspect to consider with R-6 was its eﬃcacy against
a wider range of VL and cutaneous leishmaniasis (CL) strains.
Overall, R-6 displayed potent broad-spectrum activity against
both reference strains and clinical isolates (Table 9), comparing
favorably with the standard agents sodium stibogluconate,
paromomycin, and miltefosine. This lead was also eﬀective
against the drug resistant clinical isolates L. don BHU1, L. inf
LEM5159, and L. infMHOM/FR/96/LEM3323 (IC50s of 1.3−
5.4 μM), as well as the miltefosine resistant laboratory strain L.
inf MHOM/FR/96/LEM3323 C14 MIL4 (IC50 of 0.59 μM).
These data conﬁrm that R-6 has excellent potential as a therapy
for VL and may have an additional application for the treatment
of CL (the more common skin lesion form of leishmaniasis).1
SAR of 6-Substituted 2-Nitroimidazo(or 2-
Nitrotriazolo)oxazines for Chagas Disease. While the
primary objective of this reinvestigation of pretomanid
analogues was to develop a backup drug candidate for VL,
retrospective screening against the protozoan parasites T. cruzi
and T. brucei presented an opportunity to assess the possible
capacity of these compounds to treat Chagas disease and
human African trypanosomiasis (HAT), respectively. A brief
inspection of Tables 1−4 found that only one compound (116)
had submicromolar activity against HAT (T. brucei IC50 of 0.63
μM), and this hit could be disregarded on the basis of its less
favorable mouse PK proﬁle, inferior aqueous solubility, and
Table 8. Additional Comparative Data for Lead Compounds
4 and R-6
property 4a R-6
molecular weight (Da) 359.3 345.2
LogD (measured) 3.10 2.59
thermodynamic solubility (μM) at pH 7.4 2.8 23
permeability, Papp (×10−6 cm/s) A to B/B to A 22.6/24.7b 32.4/18.9c
plasma protein binding (%)
mouse 96.2 86.7
rat 93.2 82.1
hamster 92.4 87.2
human 93.9 85.2
mutagenic eﬀect (Ames test) no nod
hERG IC50 (μM) 10.5 >30
CYP3A4 IC50 (μM) >25 >40
MABA MIC (μM) 0.046 31e
LORA MIC (μM) 5.9 >128
aMost data from refs 24 and 25. bCaco-2 data from ref 61. cMDCK-
MDR1 data; no P-gp-mediated eﬄux. dNot mutagenic in strains TA98
and TA100, in the presence or absence of metabolic activation (S9
fraction). eSingle MIC against M. tb, determined under aerobic
conditions.
Table 9. Inhibitory Activity of R-6 and Clinical VL Drugs
against Diﬀerent Leishmania Strains
IC50 (μM)
a
strain (origin) R-6 SSGb Amp Bc MILd PMe
VL Strains
L. don MHOM/IN/80/DD8
(India)
0.22 54.3 0.02 2.50 >30
L. don MHOM/ET/67/HU3
(Ethiopia)
0.33 NT 0.05 2.05 NT
L. inf MHOM/MA/67/
ITMAP263 (Morocco)
0.51 NT NT 2.30 136
L. don MHOM/SD/62/
1SCL2D (Sudan)
2.16 NT NT NT NT
L. inf MHOM/FR/96/
LEM3323 C14 MIL4
(France)f
0.59 NT NT >20 78.5
VL Clinical Isolates
L. don BHU1 (India)g 1.34 >150 0.20 3.80 >30
L. don SUKA001 (Sudan) 0.57 29.9 0.05 2.13 >30
L. don GR265 (Ethiopia) 0.19 14.5 0.05 4.60 >30
L. inf LEM5695 (Algeria; dog) 1.77 NT NT 1.86 165
L. infMCAN/BR/2002/BH400
(Brazil; dog)
1.23 NT NT 1.11 64.1
L. inf L3034 (Paraguay; HIV
patient)
0.75 NT NT 1.25 87.7
L. inf LEM5159 (France; HIV
patient)f,h
5.41 NT NT >20 64.9
L. inf LEM3323 (France; HIV
patient)h
2.22 NT NT 0.74 142
CL Strains
Leishmania aethiopica MHOM/
ET/84/KH (Ethiopia)
3.17 NT 0.11 36.1 NT
Leishmania amazonensis
MPRO/BR/72/M1841
(Brazil)i
4.68 NT 0.13 15.0 NT
Leishmania major MHOM/SA/
85/JISH118 (Saudi Arabia)
2.34 NT 0.05 22.3 NT
Leishmania mexicana MNYC/
BZ/62/M379 (Belize)
1.17 NT 0.08 6.55 NT
Leishmania panamensis
MHOM/PA/67/Boynton
(Panama)
0.34 NT 0.07 21.3 NT
Leishmania tropica Anwari
(Syrian clinical isolate)
1.57 >100 0.11 8.22 NT
aNT means not tested; some data for clinical VL drugs from refs 26
and 62. bSodium stibogluconate (IC50 in micrograms per milliliter).
cAmphotericin B. dMiltefosine. eParomomycin. fResistant to miltefo-
sine. gResistant to sodium stibogluconate. hFailed amphotericin B
treatment. iDsRed2 transgenic strain.
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poor MDCK-MDR1 cell permeability.36 Conversely, like 7-
substituted 2-nitroimidazooxazines,24 the majority of com-
pounds displayed interesting potencies against T. cruzi (IC50s of
0.025−1 μM). The selective anti-Chagas activity of nitro-
triazolooxazines (e.g., 49; T. cruzi IC50 of 0.25 μM vs >64 μM
against L. inf) was particularly striking, being reminiscent of that
of a nitrotriazolooxazole analogue of 4.25 However, further
scrutiny revealed that the enantiomers of 48 were roughly
equipotent (Table 3), while the racemic nitrotriazole counter-
parts of key VL leads R-6, R-84, and R-136 (47, 88, and 139,
respectively) were 9−68-fold less active, suggesting limited
utility for this class.
Aside from the less suitable reversed linker congeners (24−
26, 116, and 117) and O-linked biaryls (R-157, R-160, R-161,
R-168, and R-171), the most potent 6-substituted 2-nitro-
imidazooxazine anti-Chagas leads were para-linked phenyl-
pyridines (e.g., R-84, R-89, R-90, R-92, and R-93; IC50s of
0.025−0.078 μM). Here, the 6R enantiomers were clearly
superior (by 15- to >400-fold), and the 2-pyridine isomer was
preferred, although N-oxidation of the pyridine ring (R-85) was
strongly deactivating (77-fold). In the monoaryl subset,
arylpropargyl ether R-122 and phenyl ether R-6 seemed highly
promising (IC50s of 0.11 and 0.15 μM, respectively), with the
latter favored on PK and solubility grounds, whereas similarly
active benzylamines R-148 and R-149 were expected to show
rapid metabolism.36 Overall, given the signiﬁcant hERG liability
and higher level of plasma protein binding of the phenyl-
pyridines (e.g., 97.9% for R-84 in mice), R-6 was also regarded
as the best new lead for Chagas disease, although its mechanism
of action for this application remains to be determined.
■ CONCLUSIONS
In response to a compelling clinical need for more satisfactory
VL treatments, recent eﬀorts have been made to reposition
leads from other therapeutic areas, seeking to accelerate new
drug development. Promising results with antitubercular
nitroimidazooxazoles and 7-substituted 2-nitroimidazooxazines
encouraged us to evaluate additional scaﬀolds, e.g., nitro-
imidazooxazepines and methylated or reversed C-6 linker
analogues of pretomanid, but these lacked suﬃcient potency
and/or suitable PK and eﬃcacy in the L. don mouse model.
However, phenotypic screening of our pretomanid analogue
library and follow-up IC50 testing unveiled more active hits
spanning a wide lipophilicity range (CLogP values of 1.2−4.5),
including several with better solubility and microsomal stability,
e.g., phenylpyridines and benzamide S-151. This work also
pointed to the generally improved activities of novel 6R
enantiomers, which was conﬁrmed for phenylpyridines through
comparative appraisal in the mouse VL model. Further studies
in this series established that a 4-triﬂuoromethoxy phenyl
substituent, para linkage, and a proximal 2-pyridine ring were
preferred for good in vivo PK and eﬃcacy, with two such leads
(R-84 and R-89) giving ≥99% parasite clearance in the L. inf
hamster model at 50 mg/kg b.i.d. These compounds also
showed high potencies against T. cruzi, but unexpectedly high
levels of hERG inhibition ultimately terminated their develop-
ment.
Meanwhile, investigation of the C-6 linker group revealed
that the parent ether moiety in R-1 (OCH2) was nonoptimal
for VL, with shorter and longer chain variants (O and
OCH2CC, respectively) improving potency against L. inf
(whereas O-carbamate and N-linked alternatives were poor).
Although O-linked phenylpyridine R-168 displayed superb
activity in the mouse VL model (99.7% reduction in parasite
burden at 6.25 mg/kg, similar to the case for 4), we elected to
focus instead on two less lipophilic monoaryl leads (R-6 and
pyridine R-136), having superior solubility values (12−110 μg/
mL), low hERG risk, and excellent PK proﬁles in three species
(mouse, rat, and hamster). Both compounds delivered high
eﬃcacies in the chronic infection hamster model (≥97%
inhibition at 25 mg/kg, b.i.d.) and showed weakened binding to
plasma proteins, although a positive Ames test for pyridine R-
136 dissuaded its further advancement and earmarked R-6 as
the favored VL backup candidate to 3. Finally, like the
phenylpyridines, R-6 also demonstrated interesting activity
against T. cruzi, whereas nitrotriazolooxazine congeners of such
leads were less eﬀective. These results provide new insights into
the exciting potential of bicyclic nitroimidazoles as novel
therapies for the treatment of some challenging neglected
diseases.
■ EXPERIMENTAL SECTION
Combustion analyses were performed by the Campbell Micro-
analytical Laboratory, University of Otago, Dunedin, New Zealand.
Melting points were determined using an Electrothermal IA9100
melting point apparatus and are as read. NMR spectra were measured
on a Bruker Avance 400 spectrometer at 400 MHz for 1H and 100
MHz for 13C and were referenced to Me4Si or solvent resonances.
Chemical shifts and coupling constants were recorded in units of parts
per million and hertz, respectively. High-resolution electron impact
(HREIMS), chemical ionization (HRCIMS), and fast atom bombard-
ment (HRFABMS) mass spectra were recorded on a VG-70SE mass
spectrometer at a nominal 5000 resolution. High-resolution electro-
spray ionization (HRESIMS) mass spectrometry was conducted on a
Bruker micrOTOF-Q II mass spectrometer. Low-resolution atmos-
pheric-pressure chemical ionization (APCI) mass spectra were
obtained for organic solutions using a ThermoFinnigan Surveyor
MSQ mass spectrometer connected to a Gilson autosampler. Optical
rotations were measured on a Schmidt + Haensch Polartronic NH8
polarimeter. Column chromatography was performed on silica gel
(Merck 230−400 mesh). Chromatographed compounds were typically
further puriﬁed by crystallization from two solvent combinations, e.g.,
CH2Cl2 and n-hexane, EtOAc and n-hexane, Et2O and n-pentane, or
CH2Cl2 and n-pentane (occasionally, Et2O was added to the latter
combination to induce solidiﬁcation, while some compounds required
cooling at −20 °C); more polar compounds were ﬁrst dissolved in a
minimum of 10% MeOH/CH2Cl2 and slowly diluted with n-hexane to
give the solid product. Thin-layer chromatography was performed on
aluminum-backed silica gel plates (Merck 60 F254), with visualization
of components by UV light (254 nm), I2, or KMnO4 staining. Tested
compounds (including batches screened in vivo) were all ≥95% pure,
as determined by combustion analysis (results within 0.4% of
theoretical values) and/or by HPLC conducted on an Agilent 1100
system with diode array detection, using a 150 mm × 3.2 mm Altima 5
μm reversed phase C18 column or a 150 mm × 4.6 mm Zorbax
Eclipse XDB 5 μm C8 column and eluting with a gradient (40 to
100%) of 80% CH3CN/water in 45 mM ammonium formate buﬀer
(pH 3.5). Finally, the chiral purity of lead R-6 was assessed by HPLC
performed on a Shimadzu 2010 system with diode array detection,
employing a 150 mm × 4.6 mm CHIRALPAK AY-H 5 μm analytical
column and isocratic elution with 20% EtOH/n-heptane.
Compounds of Table 1. The following section details the
syntheses of compounds 14, 39, and 41 of Table 1, via representative
procedures and key intermediates, as described in Scheme 1. For the
syntheses of the other compounds in Table 1, see the Supporting
Information.
Synthesis of 14 (Scheme 1A). Procedure A: 1-[(tert-
Butyldimethylsilyl)oxy]-3-(2,4-dinitro-1H-imidazol-1-yl)-2-methyl-
propan-2-ol (10). A mixture of 2,4-dinitro-1H-imidazole (8) (1.00 g,
6.33 mmol) and tert-butyldimethyl[(2-methyloxiran-2-yl)methoxy]-
silane33 (9) (1.81 g, 8.94 mmol) under N2 was stirred at 75 °C for 18
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h. The resulting cooled mixture was diluted with EtOAc (250 mL) and
washed with aqueous NaHCO3 (150 mL) and brine (125 mL), back-
extracting with EtOAc (150 mL). The combined extracts were dried
(Na2SO4) and then evaporated to dryness under reduced pressure, and
the remaining oil was chromatographed on silica gel. Elution with 10−
33% EtOAc/petroleum ether gave 10 (0.92 g, 40%) as a yellow oil: 1H
NMR (CDCl3) δ 7.98 (s, 1 H), 4.75 (d, J = 14.0 Hz, 1 H), 4.53 (d, J =
14.0 Hz, 1 H), 3.54 (d, J = 10.2 Hz, 1 H), 3.46 (d, J = 10.1 Hz, 1 H),
2.52 (br s, 1 H), 1.17 (s, 3 H), 0.91 (s, 9 H), 0.09 (2 s, 2 × 3 H);
HRCIMS (NH3) calcd for C13H25N4O6Si m/z [M + H]
+ 361.1543,
found 361.1545.
Procedure B: 1-{3-[(tert-Butyldimethylsilyl)oxy]-2-methyl-2-[(tet-
rahydro-2H-pyran-2-yl)oxy]propyl}-2,4-dinitro-1H-imidazole (11). A
mixture of alcohol 10 (248 mg, 0.688 mmol), 3,4-dihydro-2H-pyran
(0.32 mL, 3.51 mmol), and PPTS (95 mg, 0.378 mmol) in anhydrous
CH2Cl2 (10 mL) under N2 was stirred at 20 °C for 5 h. The resulting
solution was diluted with CH2Cl2 (100 mL) and washed with aqueous
NaHCO3 (2 × 50 mL), water (50 mL), and brine (50 mL), back-
extracting with CH2Cl2 (50 mL). The combined extracts were dried
(Na2SO4) and then evaporated to dryness under reduced pressure, and
the remaining oil was chromatographed on silica gel. Elution with 10%
EtOAc/petroleum ether gave 11 (234 mg, 76%) as a yellow oil (a 1:1
mixture of diastereomers): 1H NMR (CDCl3) δ 8.25, 7.99 (2 s, 1 H),
4.88 (d, J = 13.8 Hz, 0.5 H), 4.87 (d, J = 14.0 Hz, 0.5 H), 4.84−4.72
(m, 1 H), 4.62 (d, J = 14.0 Hz, 0.5 H), 4.54 (d, J = 13.8 Hz, 0.5 H),
3.73−3.65 (m, 1 H), 3.60−3.36 (m, 2 H), 3.29 (d, J = 10.6 Hz, 0.5 H),
3.26 (d, J = 10.7 Hz, 0.5 H), 1.95−1.35 (m, 6 H), 1.33, 1.25 (2 s, 3 H),
0.94, 0.87 (2 s, 9 H), 0.10 (2 s, 3 H), 0.04, 0.02 (2 s, 3 H); HRCIMS
(NH3) calcd for C18H33N4O7Si m/z [M + H]
+ 445.2119, found
445.2125.
Procedure C: 6-Methyl-2-nitro-6-[(tetrahydro-2H-pyran-2-yl)oxy]-
6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (12). A solution of silyl
ether 11 (230 mg, 0.517 mmol) in anhydrous THF (6 mL) under N2
was treated with TBAF (1.5 mL of a 1 M solution in THF, 1.50
mmol), and the mixture was stirred at 20 °C for 1 h. The resulting
solution was concentrated under reduced pressure, then diluted with
EtOAc (50 mL), and washed with aqueous NaHCO3 (50 mL) and
brine (50 mL), back-extracting with EtOAc (2 × 50 mL). The
combined extracts were dried (Na2SO4) and then evaporated to
dryness under reduced pressure, and the residue was chromatographed
on silica gel. Elution with 5% MeOH/CH2Cl2 gave 12 (130 mg, 89%)
as a white solid (a 1:1 mixture of diastereomers): mp (CH2Cl2/
hexane) 153−156 °C; 1H NMR (CDCl3) δ 7.40, 7.37 (2 s, 1 H),
5.03−4.95 (m, 1 H), 4.54 (dd, J = 11.6, 2.3 Hz, 0.5 H), 4.44 (dd, J =
11.8, 2.7 Hz, 0.5 H), 4.34 (dd, J = 12.7, 2.7 Hz, 0.5 H), 4.18 (d, J =
11.6 Hz, 0.5 H), 4.11 (d, J = 11.7 Hz, 0.5 H), 4.09 (dd, J = 12.5, 2.3
Hz, 0.5 H), 3.89 (d, J = 12.6 Hz, 0.5 H), 3.89−3.81 (m, 1 H), 3.57−
3.44 (m, 1 H), 3.42−3.33 (m, 0.5 H), 1.92−1.38 (m, 9 H); APCI MS
m/z 284 [M + H]+.
Procedure D: 6-Methyl-2-nitro-6,7-dihydro-5H-imidazo[2,1-b]-
[1,3]oxazin-6-ol (13). A solution of THP ether 12 (120 mg, 0.424
mmol) in MeOH (10 mL) was treated with methanesulfonic acid
(52.6 mg, 0.547 mmol), and the mixture was stirred at 20 °C for 1 h.
The resulting solution was neutralized with aqueous NaHCO3; then
the solvents were removed under reduced pressure, and the residue
was chromatographed on silica gel. Elution with 5% MeOH/CH2Cl2
gave 13 (80 mg, 95%) as a white solid: mp (MeOH/CH2Cl2/hexane)
185−188 °C; 1H NMR [(CD3)2SO] δ 8.05 (s, 1 H), 5.50 (br s, 1 H),
4.26 (d, J = 11.1 Hz, 1 H), 4.12 (dd, J = 11.1, 2.6 Hz, 1 H), 4.00 (d, J =
12.6 Hz, 1 H), 3.89 (dd, J = 12.6, 2.4 Hz, 1 H), 1.24 (s, 3 H);
HREIMS calcd for C7H9N3O4 m/z (M
+) 199.0593, found 199.0591.
Procedure E: 6-Methyl-2-nitro-6-{[4-(triﬂuoromethoxy)benzyl]-
oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (14). A solution of
alcohol 13 (50.7 mg, 0.255 mmol) and 4-(triﬂuoromethoxy)benzyl
bromide (65 μL, 0.406 mmol) in anhydrous DMF (3 mL) under N2
was treated with 60% NaH (20 mg, 0.50 mmol), and the mixture was
stirred at 20 °C for 3 h. The resulting mixture was diluted with EtOAc
(150 mL) and washed with aqueous NaHCO3 (50 mL), water (2 × 50
mL), and brine (50 mL), back-extracting with EtOAc (100 mL). The
combined extracts were dried (Na2SO4) and then evaporated to
dryness under reduced pressure, and the residue was chromatographed
on silica gel. Elution with 1−2% MeOH/CH2Cl2 gave 14 (45 mg,
47%) as a white solid: mp (EtOAc/hexane) 139−141 °C; 1H NMR
[(CD3)2SO] δ 7.99 (s, 1 H), 7.31 (br d, J = 9.0 Hz, 2 H), 7.28 (br d, J
= 9.0 Hz, 2 H), 4.60 (dd, J = 11.9, 2.8 Hz, 1 H), 4.56 (br s, 2 H), 4.37
(d, J = 11.8 Hz, 1 H), 4.24 (dd, J = 13.2, 2.6 Hz, 1 H), 4.07 (d, J = 13.1
Hz, 1 H), 1.36 (s, 3 H); 13C NMR [(CD3)2SO] δ 147.5, 147.0, 142.2,
137.8, 129.0 (2 C), 120.9 (2 C), 120.0 (q, JC−F = 255.9 Hz), 117.8,
70.6, 69.2, 62.9, 50.7, 17.0. Anal. Calcd for C15H14F3N3O5: C, 48.26;
H, 3.78; N, 11.26. Found: C, 48.23; H, 3.98; N, 11.31.
Synthesis of 39 and 41 (Scheme 1D). 2-Bromo-4-nitro-1-{3-
[(tetrahydro-2H-pyran-2-yl)oxy]-4-[(triisopropylsilyl)oxy]butyl}-1H-
imidazole (35). Reaction of 4-(2-bromo-4-nitro-1H-imidazol-1-yl)-1-
[(triisopropylsilyl)oxy]butan-2-ol24 (34) with 3,4-dihydro-2H-pyran
(4.0 equiv) and PPTS, using procedure B for 1 day (but washing with
aqueous NaHCO3 only and extracting the product four times with
CH2Cl2), followed by chromatography of the product on silica gel,
eluting with 25−50% CH2Cl2/petroleum ether (forerunners) and then
with CH2Cl2, gave 35 (100%) as a colorless oil (a 1:1 mixture of
diastereomers): 1H NMR (CDCl3) δ 8.20, 7.82 (2 s, 1 H), 4.69−4.58
(m, 1 H), 4.31−4.10 (m, 2 H), 4.08−3.99 (m, 1 H), 3.92−3.43 (m, 4
H), 2.34−2.23 (m, 0.5 H), 2.12−2.01 (m, 1 H), 1.94−1.41 (m, 6.5 H),
1.18−0.96 (m, 21 H); HRFABMS calcd for C21H39BrN3O5Si m/z [M
+ H]+ 522.1822, 520.1842, found 522.1838, 520.1826.
4-(2-Bromo-4-nitro-1H-imidazol-1-yl)-2-[(tetrahydro-2H-pyran-
2-yl)oxy]butan-1-ol (36). Reaction of silyl ether 35 with TBAF (1.1
equiv), using procedure C for 3 h (extracting the product ﬁve times
with EtOAc), followed by chromatography of the product on silica gel,
eluting with 33% EtOAc/petroleum ether (forerunners) and then with
33−50% EtOAc/petroleum ether, gave 36 (91%) as a white solid (a
3:1 mixture of diastereomers): mp (Et2O/CH2Cl2/pentane) 89−91
°C; 1H NMR (CDCl3) δ 8.16, 7.79 (2 s, 1 H), 4.65−4.50 (m, 1 H),
4.29−4.12 (m, 2 H), 4.08−3.97 (m, 1 H), 3.85−3.46 (m, 4 H), 2.12−
1.73 (m, 5 H), 1.65−1.45 (m, 4 H). Anal. Calcd for C12H18BrN3O5: C,
39.58; H, 4.98; N, 11.54. Found: C, 39.85; H, 5.12; N, 11.57.
Procedure F: 2-Nitro-7-[(tetrahydro-2H-pyran-2-yl)oxy]-5,6,7,8-
tetrahydroimidazo[2,1-b][1,3]oxazepine (37). A solution of alcohol
36 (730 mg, 2.00 mmol) in anhydrous DMF (8 mL) under N2 at 0 °C
was treated with 60% NaH (148 mg, 3.70 mmol) and then quickly
degassed and resealed under N2. The mixture was stirred at 20 °C for
3.5 h and then cooled to −78 °C (CO2/acetone), the reaction
quenched with ice/aqueous NaHCO3 (50 mL), and the mixture
extracted with EtOAc (7 × 50 mL). The extracts were washed with
brine (50 mL) and then evaporated to dryness under reduced pressure
(at 30 °C), and the residue was chromatographed on silica gel. Elution
with 0−33% EtOAc/petroleum ether ﬁrst gave forerunners, and then
further elution with 50% EtOAc/petroleum ether gave the crude
product, which was chromatographed again on silica gel. Elution with
0−2% EtOAc/CH2Cl2 ﬁrst gave forerunners, and then further elution
with 3−4% EtOAc/CH2Cl2 gave 37 (144 mg, 25%) as a white solid:
mp (CH2Cl2/hexane) 158−160 °C; 1H NMR (CDCl3) δ 7.48 (s, 1
H), 4.83−4.75 (m, 1 H), 4.39−4.04 (m, 4 H), 3.96−3.82 (m, 2 H),
3.60−3.50 (m, 1 H), 2.25−2.02 (m, 2 H), 1.92−1.71 (m, 2 H), 1.69−
1.50 (m, 4 H). Anal. Calcd for C12H17N3O5: C, 50.88; H, 6.05; N,
14.83. Found: C, 51.08; H, 6.08; N, 14.89.
2-Nitro-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]oxazepin-7-ol (38).
A solution of THP ether 37 (137 mg, 0.484 mmol) in MeOH (14
mL) was treated with 3.3 M HCl (0.47 mL, 1.55 mmol). The mixture
was stirred at 20 °C for 5 h, cooled to −20 °C, and neutralized with a
solution of NH3 in MeOH (0.8 mL of a 7 M solution). The resulting
mixture was evaporated to dryness under reduced pressure (at 30 °C),
and the residue was chromatographed on silica gel. Elution with 0−
25% EtOAc/CH2Cl2 ﬁrst gave forerunners, and then further elution
with 25% EtOAc/CH2Cl2 gave 38 (91 mg, 94%) as a white solid: mp
(MeOH/CH2Cl2/hexane) 185−187 °C; 1H NMR [(CD3)2SO] δ 8.15
(s, 1 H), 5.28 (br s, 1 H), 4.22 (ddd, J = 14.1, 9.1, 2.0 Hz, 1 H), 4.19−
4.09 (m, 1 H), 4.02−3.91 (m, 3 H), 2.09−1.98 (m, 1 H), 1.88−1.76
(m, 1 H). Anal. Calcd for C7H9N3O4: C, 42.21; H, 4.55; N, 21.10.
Found: C, 42.41; H, 4.72; N, 21.28.
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Procedure G: 2-Nitro-7-{[4-(triﬂuoromethoxy)benzyl]oxy}-5,6,7,8-
tetrahydroimidazo[2,1-b][1,3]oxazepine (39) and 2-Nitro-7-({[4-
(triﬂuoromethoxy)benzyl]oxy}methyl)-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazine (41). A mixture of alcohol 38 (51.0 mg, 0.256 mmol)
and 4-(triﬂuoromethoxy)benzyl bromide (0.205 mL, 1.28 mmol) in
anhydrous DMF (1.5 mL) under N2 at 0 °C was treated with 60%
NaH (17.5 mg, 0.438 mmol) and then quickly degassed and resealed
under N2. The mixture was stirred at 20 °C for 130 min and then
cooled to −78 °C (CO2/acetone), the reaction quenched with ice/
aqueous NaHCO3 (10 mL), and the mixture added to brine (40 mL)
and extracted with CH2Cl2 (5 × 50 mL). The combined extracts were
evaporated to dryness under reduced pressure (at 30 °C), and the
residue was chromatographed on silica gel. Elution with 0−50%
EtOAc/petroleum ether ﬁrst gave forerunners, and then further
elution with 50% EtOAc/petroleum ether gave 39 (37 mg, 39%) as a
white solid: mp (CH2Cl2/pentane) 119−121 °C; 1H NMR
[(CD3)2SO] δ 8.18 (s, 1 H), 7.51 (br d, J = 8.8 Hz, 2 H), 7.36 (br
d, J = 7.9 Hz, 2 H), 4.66 (s, 2 H), 4.36 (dd, J = 12.6, 4.6 Hz, 1 H),
4.26−4.13 (m, 2 H), 4.04 (ddd, J = 14.2, 6.4, 3.0 Hz, 1 H), 3.95−3.86
(m, 1 H), 2.19−2.02 (m, 2 H); 13C NMR [(CD3)2SO] δ 151.1, 147.6
(q, JC−F = 1.5 Hz), 140.6, 137.9, 129.3 (2 C), 120.9 (2 C), 120.4, 120.1
(q, JC−F = 256.1 Hz), 74.5, 73.3, 68.7, 42.0, 30.1. Anal. Calcd for
C15H14F3N3O5·0.5H2O: C, 47.13; H, 3.96; N, 10.99. Found: C, 46.86;
H, 3.63; N, 10.82. HPLC purity of 100%.
Further elution of the column described above with 50−75%
EtOAc/petroleum ether gave crude 41, which was chromatographed
again on silica gel (as before) to give 4124 (34 mg, 36%) as a cream
solid: mp (EtOAc/hexane) 163−164 °C (lit.24 mp 158−160 °C); 1H
NMR (CDCl3) δ 7.42 (s, 1 H), 7.34 (br d, J = 8.7 Hz, 2 H), 7.20 (br d,
J = 8.6 Hz, 2 H), 4.61 (s, 2 H), 4.61−4.54 (m, 1 H), 4.15 (ddd, J =
12.4, 5.7, 3.7 Hz, 1 H), 4.06 (ddd, J = 12.4, 10.0, 5.8 Hz, 1 H), 3.83
(dd, J = 10.6, 4.4 Hz, 1 H), 3.78 (dd, J = 10.7, 4.9 Hz, 1 H), 2.39−2.21
(m, 2 H); APCI MS m/z 374 [M + H]+; HPLC purity of 100%.
Compounds of Table 2. The following section details the
syntheses of compounds R-58 and R-69 of Table 2, via representative
procedures and key intermediates, as described in Scheme 2. For the
syntheses of the other compounds in Table 2, see the Supporting
Information.
Synthesis of R-58 (Scheme 2A). (6R)-6-[(2-Iodobenzyl)oxy]-2-
nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (57). Reaction of
(6R)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-ol32 (56)
with 2-iodobenzyl chloride (3.0 equiv) and NaH (1.6 equiv), using
procedure G for 3.5 h, followed by chromatography of the product on
silica gel, eluting with 0−0.25% MeOH/CH2Cl2 (forerunners) and
then with 0.25−0.3% MeOH/CH2Cl2, gave 57 (91%) as a light yellow
solid: mp (Et2O) 118−119 °C; 1H NMR (CDCl3) δ 7.85 (br d, J = 7.8
Hz, 1 H), 7.40 (s, 1 H), 7.37−7.33 (m, 2 H), 7.08−7.00 (m, 1 H), 4.72
(d, J = 12.0 Hz, 1 H), 4.72−4.65 (m, 1 H), 4.64 (d, J = 12.0 Hz, 1 H),
4.40 (br dd, J = 12.1, 0.9 Hz, 1 H), 4.25−4.19 (m, 3 H). Anal. Calcd
for C13H12IN3O4: C, 38.92; H, 3.02; N, 10.47. Found: C, 39.08; H,
2.98; N, 10.44.
Procedure H: (6R)-2-Nitro-6-{[4′-(triﬂuoromethoxy)(1,1′-biphen-
yl)-2-yl]methoxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (R-
58). A mixture of iodide 57 (435 mg, 1.08 mmol), [4-
(triﬂuoromethoxy)phenyl]boronic acid (401 mg, 1.95 mmol), and
Pd(dppf)Cl2 (56 mg, 0.077 mmol) in DMF (6 mL) and aqueous
KHCO3 (2 mL of a 2 M solution, 4.0 mmol) was degassed, and then
N2 was added. The resulting mixture was stirred at 75 °C for 4 h, and
then cooled, diluted with brine (100 mL), and extracted with CH2Cl2
(3 × 100 mL). The extracts were evaporated to dryness under reduced
pressure, and the residue was chromatographed on silica gel. Elution
with CH2Cl2 ﬁrst gave forerunners, and then further elution with 2%
MeOH/CH2Cl2 gave R-58 (218 mg, 46%) as a cream solid: mp
(CH2Cl2/hexane) 133−135 °C; 1H NMR [(CD3)2SO] δ 8.00 (s, 1
H), 7.50−7.44 (m, 3 H), 7.44−7.35 (m, 4 H), 7.33−7.26 (m, 1 H),
4.57−4.49 (m, 2 H), 4.49 (d, J = 10.9 Hz, 1 H), 4.42 (br d, J = 11.8
Hz, 1 H), 4.22−4.12 (m, 3 H); 13C NMR [(CD3)2SO] δ 147.6 (q,
JC−F = 1.5 Hz), 147.1, 142.1, 140.0, 139.3, 134.5, 130.7 (2 C), 130.0,
129.9, 128.3, 127.9, 120.6 (2 C), 120.1 (q, JC−F = 256.4 Hz), 117.9,
68.1, 67.8, 66.8, 46.5. Anal. Calcd for C20H16F3N3O5: C, 55.18; H,
3.70; N, 9.65. Found: C, 55.08; H, 3.66; N, 9.68.
Synthesis of R-69 (Scheme 2B). (6R)-6-[(2-Bromopyridin-3-
yl)methoxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
(68). Reaction of alcohol 5632 with 2-bromo-3-(bromomethyl)pyridine
(66) (1.6 equiv) and NaH (1.6 equiv), using procedure G at 0 °C for
1 h and then at 20 °C for 80 min, followed by chromatography of the
product on silica gel, eluting with 0−0.5% MeOH/CH2Cl2
(forerunners) and then with 0.5−0.67% MeOH/CH2Cl2, gave 68
(83%) as a cream solid: mp (MeOH/CH2Cl2/hexane) 189−190 °C;
1H NMR [(CD3)2SO] δ 8.32 (dd, J = 4.7, 2.0 Hz, 1 H), 8.05 (s, 1 H),
7.80 (dd, J = 7.5, 2.0 Hz, 1 H), 7.46 (dd, J = 7.5, 4.7 Hz, 1 H), 4.73−
4.66 (m, 3 H), 4.51 (br d, J = 11.7 Hz, 1 H), 4.39−4.32 (m, 2 H), 4.25
(dd, J = 13.7, 3.4 Hz, 1 H). Anal. Calcd for C12H11BrN4O4: C, 40.58;
H, 3.12; N, 15.78. Found: C, 40.81; H, 3.20; N, 15.72.
Procedure I: (6R)-2-Nitro-6-({2-[4-(triﬂuoromethoxy)phenyl]-
pyridin-3-yl}methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
(R-69). A stirred mixture of bromide 68 (60.3 mg, 0.170 mmol), [4-
(triﬂuoromethoxy)phenyl]boronic acid (60.5 mg, 0.294 mmol), and
Pd(dppf)Cl2 (29.7 mg, 0.041 mmol) in DMF (1.5 mL), toluene (1.0
mL), and EtOH (0.8 mL) was degassed for 7 min (vacuum pump),
and then N2 was added. An aqueous solution of Na2CO3 (0.45 mL of a
2 M solution, 0.90 mmol) was added by syringe; the stirred mixture
was again degassed for 8 min, and then N2 was added. The resulting
mixture was stirred at 87 °C for 190 min and then cooled, diluted with
aqueous NaHCO3 (50 mL), and extracted with CH2Cl2 (5 × 50 mL).
The combined extracts were evaporated to dryness under reduced
pressure (at 30 °C), and the residue was chromatographed on silica
gel. Elution with 0−0.5% MeOH/CH2Cl2 ﬁrst gave forerunners, and
then further elution with 0.5−0.75% MeOH/CH2Cl2 gave R-69 (62
mg, 84%) as a pale yellow solid: mp (MeOH/CH2Cl2/hexane) 246−
248 °C; 1H NMR [(CD3)2SO] δ 8.62 (dd, J = 4.7, 1.7 Hz, 1 H), 8.02
(s, 1 H), 7.89 (dd, J = 7.8, 1.6 Hz, 1 H), 7.67 (br d, J = 8.8 Hz, 2 H),
7.43 (dd, J = 7.7, 4.8 Hz, 1 H), 7.41 (br d, J = 9.0 Hz, 2 H), 4.68−4.57
(m, 3 H), 4.46 (br d, J = 11.9 Hz, 1 H), 4.31−4.17 (m, 3 H); 13C
NMR [(CD3)2SO] δ 156.2, 148.9, 148.4, 147.1, 142.1, 138.5, 138.2,
130.8 (2 C), 130.5, 122.8, 120.4 (2 C), 120.1 (q, JC−F = 256.4 Hz),
118.0, 67.8, 67.4, 67.1, 46.6. Anal. Calcd for C19H15F3N4O5: C, 52.30;
H, 3.47; N, 12.84. Found: C, 52.02; H, 3.43; N, 12.72.
Compounds of Table 3. The following section details the
syntheses of compounds R-122, R-136, R-140, R-147, R-151, and R-
155 of Table 3, via representative procedures and key intermediates, as
described in Schemes 4 and 5. For the syntheses of the other
compounds in Table 3, see the Supporting Information.
Synthesis of R-122 (Scheme 4A). (6R)-2-Nitro-6-[(prop-2-yn-1-
yl)oxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (121). A solution
of alcohol 5632 (430 mg, 2.32 mmol) and (3-bromoprop-1-yn-1-
yl)(tert-butyl)dimethylsilane41 (120) (900 mg, 3.86 mmol) in
anhydrous DMF (6 mL) under N2 was treated with 60% NaH (148
mg, 3.70 mmol), and the mixture was stirred at 20 °C for 15 min. The
resulting mixture was diluted with water (100 mL), and the precipitate
was collected by ﬁltration, washed with water and petroleum ether, and
dried. This solid was then redissolved in THF (10 mL); TBAF (6.0
mL of a 1 M solution in THF, 6.0 mmol) was added, and the mixture
was stirred at 20 °C for 30 min. The resulting mixture was diluted with
EtOAc (100 mL) and washed with water (2 × 100 mL) and brine
(100 mL), back-extracting with EtOAc (100 mL). The combined
extracts were dried (Na2SO4) and then evaporated to dryness under
reduced pressure, and the residue was chromatographed on silica gel.
Elution with 50% EtOAc/petroleum ether ﬁrst gave forerunners, and
then further elution with EtOAc gave 121 (312 mg, 60%) as a cream
solid: mp (Et2O/pentane) 81−83 °C; 1H NMR (CDCl3) δ 7.42 (s, 1
H), 4.63 (ddd, J = 12.5, 3.8, 2.1 Hz, 1 H), 4.42−4.33 (m, 3 H), 4.32
(dd, J = 16.5, 2.5 Hz, 1 H), 4.25 (dd, J = 13.1, 3.6 Hz, 1 H), 4.18 (dt, J
= 13.0, 2.5 Hz, 1 H), 2.56 (t, J = 2.4 Hz, 1 H); HRESIMS calcd for
C9H9N3NaO4 m/z [M + Na]
+ 246.0485, found 246.0484.
Procedure J: (6R)-2-Nitro-6-({3-[4-(triﬂuoromethoxy)phenyl]prop-
2-yn-1-yl}oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (R-122).
A mixture of alkyne 121 (108 mg, 0.484 mmol), 1-iodo-4-
(triﬂuoromethoxy)benzene (167 mg, 0.580 mmol), and CuI (2 mg,
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0.01 mmol) in triethylamine (5 mL) and DMF (5 mL) was purged
with N2. Pd(PPh3)2Cl2 (7 mg, 0.01 mmol) was added, and the mixture
was stirred at 70 °C for 15 min under N2 and then cooled, diluted with
water (100 mL), and extracted with EtOAc (2 × 100 mL). The
extracts were combined and evaporated to dryness under reduced
pressure, and the residue was chromatographed on silica gel. Elution
with 50% EtOAc/petroleum ether ﬁrst gave forerunners, and then
further elution with EtOAc gave R-122 (109 mg, 59%) as a cream
solid: mp 150−152 °C; 1H NMR [(CD3)2SO] δ 8.05 (s, 1 H), 7.61
(br d, J = 8.9 Hz, 2 H), 7.39 (br d, J = 8.9 Hz, 2 H), 4.66 (dt, J = 12.1,
2.4 Hz, 1 H), 4.59 (s, 2 H), 4.49 (br d, J = 12.0 Hz, 1 H), 4.41−4.37
(m, 1 H), 4.31 (dt, J = 13.6, 2.0 Hz, 1 H), 4.25 (dd, J = 13.6, 3.2 Hz, 1
H); 13C NMR [(CD3)2SO] δ 148.3 (q, JC−F = 1.5 Hz), 147.0, 142.1,
133.6 (2 C), 121.3 (2 C), 121.0, 119.9 (q, JC−F = 257.1 Hz), 118.0,
86.5, 84.7, 67.8, 66.2, 56.2, 46.6. Anal. Calcd for C16H12F3N3O5: C,
50.14; H, 3.16; N, 10.96. Found: C, 50.19; H, 3.08; N, 10.85.
Synthesis of R-136 (Scheme 4D). (6R)-2-Nitro-6-{[5-
(triﬂuoromethyl)pyridin-2-yl]oxy}-6,7-dihydro-5H-imidazo[2,1-b]-
[1,3]oxazine (R-136). A solution of alcohol 5632 (1.00 g, 5.40 mmol)
and 2-ﬂuoro-5-(triﬂuoromethyl)pyridine (265 mg, 1.61 mmol) in
anhydrous DMF (20 mL) under N2 at −10 °C was treated with 60%
NaH (275 mg, 6.88 mmol), then quickly degassed, and resealed under
N2. Then 2-ﬂuoro-5-(triﬂuoromethyl)pyridine (1.32 g, 8.00 mmol)
was added, and the mixture was stirred at −10 to 0 °C for 1 h.
Additional 2-ﬂuoro-5-(triﬂuoromethyl)pyridine (450 mg, 2.73 mmol)
was added, and the mixture was stirred at 20 °C for 130 min. The
resulting mixture was cooled to −78 °C (CO2/acetone), the reaction
quenched with ice/aqueous NaHCO3 (20 mL), and then the mixture
added to brine (100 mL) and extracted with CH2Cl2 (7 × 100 mL).
The combined extracts were evaporated to dryness under reduced
pressure (at 30 °C), and the residue was chromatographed on silica
gel. Elution with CH2Cl2 ﬁrst gave forerunners, and then further
elution with 0−2% EtOAc/CH2Cl2 gave the product, which was
triturated in Et2O (10 mL) and diluted with pentane (90 mL) to give
R-136 (1.66 g, 93%) as a cream solid: mp 140−141 °C; 1H NMR
[(CD3)2SO] δ 8.68−8.64 (m, 1 H), 8.13 (br dd, J = 8.7, 2.6 Hz, 1 H),
8.05 (s, 1 H), 7.09 (d, J = 8.7 Hz, 1 H), 5.86−5.79 (m, 1 H), 4.75 (dt, J
= 12.3, 2.1 Hz, 1 H), 4.71 (br d, J = 12.2 Hz, 1 H), 4.49 (dd, J = 14.0,
3.4 Hz, 1 H), 4.42 (br d, J = 14.1 Hz, 1 H); 13C NMR [(CD3)2SO] δ
163.9, 146.9, 144.8 (q, JC−F = 4.5 Hz), 142.1, 137.2 (q, JC−F = 3.1 Hz),
124.0 (q, JC−F = 271.5 Hz), 119.7 (q, JC−F = 32.6 Hz), 118.0, 112.1,
68.3, 64.3, 46.6. Anal. Calcd for C12H9F3N4O4: C, 43.65; H, 2.75; N,
16.97. Found: C, 43.80; H, 2.69; N, 17.18.
Synthesis of R-140 (Scheme 4E). Procedure K: (6R)-2-Nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl [4-(Triﬂuoromethoxy)-
phenyl]carbamate (R-140). 1-Isocyanato-4-(triﬂuoromethoxy)-
benzene (70 μL, 0.464 mmol) and CuCl (3.3 mg, 0.033 mmol)
were successively added to a solution of alcohol 5632 (54.2 mg, 0.293
mmol) in anhydrous DMF (0.7 mL) under N2. The mixture was
brieﬂy degassed and resealed under N2 and then stirred at 20 °C for 33
h. The resulting solution was treated with ice/water (5 mL), added to
brine (50 mL), and extracted with CH2Cl2 (6 × 50 mL). The
combined extracts were evaporated to dryness under reduced pressure
(at 30 °C), and the residue was chromatographed on silica gel. Elution
with 0−3% EtOAc/CH2Cl2 ﬁrst gave forerunners, and then further
elution with 3−4% EtOAc/CH2Cl2 gave R-140 (108 mg, 95%) as a
cream solid: mp (CH2Cl2/hexane) 203−205 °C; 1H NMR
[(CD3)2SO] δ 10.11 (br s, 1 H), 8.09 (s, 1 H), 7.56 (br d, J = 8.8
Hz, 2 H), 7.30 (br d, J = 8.6 Hz, 2 H), 5.47−5.41 (m, 1 H), 4.69−4.60
(m, 2 H), 4.43 (dd, J = 14.0, 3.4 Hz, 1 H), 4.33 (br dd, J = 14.0, 1.1
Hz, 1 H); 13C NMR [(CD3)2SO] δ 152.2, 146.8, 143.3 (q, JC−F = 1.6
Hz), 142.1, 137.9, 121.7 (2 C), 120.1 (q, JC−F = 255.5 Hz), 119.6 (2
C), 117.9, 68.5, 62.9, 47.0. Anal. Calcd for C14H11F3N4O6: C, 43.31;
H, 2.86; N, 14.43. Found: C, 43.43; H, 2.73; N, 14.35.
Syntheses of R-147 and R-151 (Scheme 5A). (6S)-2-Nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl 4-Methylbenzene-1-sul-
fonate (144). A mixture of (6S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-
b][1,3]oxazin-6-ol32 (65) (5.00 g, 27.0 mmol) and 4-methylbenzene-
1-sulfonyl chloride (10.4 g, 54.6 mmol) in anhydrous pyridine (25
mL) was stirred at 49 °C for 17 h. The cooled solution was added to
crushed ice (∼0.7 L), and the resulting precipitate was collected by
ﬁltration, washing with water and petroleum ether, to give 144 (8.62 g,
94%) as a cream solid: mp 238−242 °C dec; 1H NMR [(CD3)2SO] δ
8.01 (s, 1 H), 7.85 (br d, J = 8.3 Hz, 2 H), 7.51 (br d, J = 8.0 Hz, 2 H),
5.41−5.34 (m, 1 H), 4.56 (br d, J = 12.3 Hz, 1 H), 4.42 (dt, J = 12.6,
2.6 Hz, 1 H), 4.35 (dd, J = 14.3, 3.2 Hz, 1 H), 4.20 (dt, J = 14.4, 1.9
Hz, 1 H), 2.44 (s, 3 H). Anal. Calcd for C13H13N3O6S: C, 46.02; H,
3.86; N, 12.38. Found: C, 46.25; H, 3.74; N, 12.47.
(6R)-6-Azido-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
(145). A mixture of tosylate 144 (8.61 g, 25.4 mmol) and sodium azide
(2.48 g, 38.1 mmol) in anhydrous DMSO (60 mL) was stirred at 64
°C for 84 h. The resulting cooled solution was added to water (250
mL) and extracted with EtOAc (5 × 250 mL); the initially formed
emulsion required ﬁltration to remove a dark brown tar. The
combined extracts were evaporated to dryness under reduced pressure
(at 50 °C), and the residue was triturated in EtOAc (45 mL), diluted
with petroleum ether (15 mL), and ﬁltered to give 145 (3.54 g, 66%)
as a brown solid. The ﬁltrate was evaporated to dryness under reduced
pressure, and the residue was chromatographed on silica gel. Elution
with 0−0.33% MeOH/CH2Cl2 ﬁrst gave forerunners, and then further
elution with 0.33−0.5% MeOH/CH2Cl2 gave crude 145, which was
chromatographed again on silica gel. Elution with Et2O ﬁrst gave
forerunners, and then further elution with 0−0.33% MeOH/CH2Cl2
gave additional 145 (363 mg, 7%) as a cream solid: mp (EtOAc/
hexane) 154−156 °C; 1H NMR [(CD3)2SO] δ 8.08 (s, 1 H), 4.67−
4.61 (m, 1 H), 4.59 (br dd, J = 11.9, 1.4 Hz, 1 H), 4.55 (ddd, J = 11.9,
2.8, 2.0 Hz, 1 H), 4.32 (dd, J = 13.5, 3.8 Hz, 1 H), 4.17 (br dt, J = 13.5,
1.8 Hz, 1 H); [α]25D 92.6 (c 1.004, DMF). Anal. Calcd for C6H6N6O3:
C, 34.29; H, 2.88; N, 39.99. Found: C, 34.57; H, 2.66; N, 40.03.
(6R)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-amine
Hydrochloride (146). Propane-1,3-dithiol (9.2 mL, 91.6 mmol) was
added to a mixture of azide 145 (3.83 g, 18.2 mmol) and triethylamine
(12.8 mL, 91.8 mmol) in anhydrous MeOH (75 mL) under N2. After
being stirred at 20 °C for 30 min, the mixture was evaporated to
dryness under reduced pressure (at 30 °C), and the residue was
chromatographed on silica gel. Elution with 0−3.5% MeOH/CH2Cl2
ﬁrst gave forerunners, and then further elution with 5−8% MeOH/
CH2Cl2 gave the product free base (2.25 g, 67%) as a yellow solid,
which was used directly: 1H NMR [(CD3)2SO] δ 8.06 (s, 1 H), 4.35
(br dd, J = 10.8, 2.1 Hz, 1 H), 4.19−4.10 (m, 2 H), 3.76 (ddd, J = 12.4,
5.5, 1.0 Hz, 1 H), 3.54−3.13 (m, 3 H); APCI MS m/z 185 [M + H]+.
This free base was dissolved in MeOH (10 mL) and dioxane (10 mL)
and treated with a solution of HCl in dioxane (4.6 mL of a 4 M
solution, 18.4 mmol), and then the mixture was diluted with Et2O
(100 mL). The resulting oily precipitate was triturated to give 146
(2.29 g, 57%) as a bright yellow powder: mp 208 °C dec; 1H NMR
[(CD3)2SO] δ 8.73 (br s, 3 H), 8.18 (s, 1 H), 4.63 (dd, J = 12.2, 2.0
Hz, 1 H), 4.59 (dt, J = 12.1, 2.2 Hz, 1 H), 4.41 (dd, J = 14.0, 5.0 Hz, 1
H), 4.21 (br d, J = 14.1 Hz, 1 H), 4.16−4.07 (m, 1 H); [α]27D 74.7 (c
1.004, H2O); HRESIMS calcd for C6H9N4O3 m/z [M − Cl−]+
185.0669, found 185.0673.
Procedure L: (6R)-2-Nitro-N-[4-(triﬂuoromethoxy)benzyl]-6,7-di-
hydro-5H-imidazo[2,1-b][1,3]oxazin-6-amine (R-147). 4-
(Triﬂuoromethoxy)benzaldehyde (130 μL, 0.910 mmol) was added
to a mixture of amine salt 146 (120 mg, 0.544 mmol) and AcOH (65
μL, 1.14 mmol) in anhydrous DMF (5 mL) under N2. The mixture
was stirred at 20 °C for 15 min and then cooled to 0 °C. Sodium
cyanoborohydride (73 mg, 1.16 mmol) was added, and the mixture
was quickly degassed and resealed under N2 and then stirred at 20 °C
for 7 h. The resulting mixture was cooled to −78 °C (CO2/acetone),
the reaction quenched with ice/aqueous Na2CO3 (10 mL), and the
mixture added to brine (40 mL) and extracted with CH2Cl2 (6 × 50
mL). The combined extracts were evaporated to dryness under
reduced pressure (at 30 °C), and the residue was chromatographed on
silica gel. Elution with 0−0.25% MeOH/CH2Cl2 ﬁrst gave forerunners,
and then further elution with 0.33−0.5% MeOH/CH2Cl2 gave R-147
(150 mg, 77%) as a cream solid: mp (Et2O/CH2Cl2/hexane) 120−121
°C; 1H NMR [(CD3)2SO] δ 8.01 (s, 1 H), 7.45 (br d, J = 8.6 Hz, 2
H), 7.30 (br d, J = 8.0 Hz, 2 H), 4.43 (dd, J = 11.2, 2.2 Hz, 1 H), 4.38
(ddd, J = 11.3, 4.3, 1.3 Hz, 1 H), 4.16 (dd, J = 12.7, 4.1 Hz, 1 H), 3.99
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(dd, J = 12.7, 2.7 Hz, 1 H), 3.81 (br s, 2 H), 3.29−3.19 (m, 1 H), 2.83
(br s, 1 H); 13C NMR [(CD3)2SO] δ 147.4, 147.1, 142.1, 139.9, 129.6
(2 C), 120.8 (2 C), 120.1 (q, JC−F = 255.6 Hz), 118.1, 68.8, 48.8, 47.2,
46.8. Anal. Calcd for C14H13F3N4O4: C, 46.93; H, 3.66; N, 15.64.
Found: C, 47.12; H, 3.54; N, 15.89.
Procedure M: N-[(6R)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b]-
[1,3]oxazin-6-yl]-3-(triﬂuoromethoxy)benzamide (R-151). 3-
(Triﬂuoromethoxy)benzoyl chloride (205 mg, 0.913 mmol) was
added to a solution of amine salt 146 (152 mg, 0.689 mmol) and
DIPEA (0.30 mL, 1.72 mmol) in anhydrous DMF (3 mL) under N2.
The mixture was stirred at 20 °C for 10 h and then treated with ice/
water (5 mL), added to brine (40 mL), and extracted with CH2Cl2 (4
× 50 mL). The combined extracts were evaporated to dryness under
reduced pressure (at 30 °C), and the residue was chromatographed on
silica gel. Elution with 0−0.5% MeOH/CH2Cl2 ﬁrst gave forerunners,
and then further elution with 0.5−0.67% MeOH/CH2Cl2 gave R-151
(213 mg, 83%) as a cream solid: mp (Et2O/pentane) 98−101 °C dec;
1H NMR [(CD3)2SO] δ 9.01 (br d, J = 6.4 Hz, 1 H), 8.13 (s, 1 H),
7.90 (dt, J = 7.6, 1.3 Hz, 1 H), 7.83−7.78 (m, 1 H), 7.63 (dd, J = 8.0,
7.7 Hz, 1 H), 7.60−7.55 (m, 1 H), 4.69−4.61 (m, 1 H), 4.57 (dd, J =
11.2, 2.3 Hz, 1 H), 4.51 (ddd, J = 11.3, 4.1, 1.4 Hz, 1 H), 4.41 (dd, J =
13.0, 5.1 Hz, 1 H), 4.17 (ddd, J = 13.1, 3.3, 1.2 Hz, 1 H); 13C NMR
[(CD3)2SO] δ 165.4, 148.2, 147.2, 142.2, 135.9, 130.5, 126.8, 124.1,
120.1, 120.0 (q, JC−F = 256.8 Hz), 118.4, 68.5, 46.5, 41.6. Anal. Calcd
for C14H11F3N4O5: C, 45.17; H, 2.98; N, 15.05. Found: C, 45.37; H,
2.98; N, 15.07.
Synthesis of R-155 (Scheme 5B). Procedure N: N-[(6R)-2-Nitro-
6 ,7 -d ihydro-5H- imidazo[2 ,1 -b ] [1 ,3 ]oxaz in-6-y l ] -N ′ - [2 -
(tr iﬂuoromethoxy)phenyl]urea (R-155) . 1-Isocyanato-2-
(triﬂuoromethoxy)benzene (80 μL, 0.532 mmol) was added to a
solution of amine salt 146 (80.2 mg, 0.364 mmol), DIPEA (0.155 mL,
0.890 mmol), and dibutyltin diacetate (9.3 mg, 0.026 mmol) in
anhydrous DMF (2 mL) under N2. The mixture was stirred at 20 °C
for 18 h and then treated with ice/water (5 mL), added to brine (40
mL), and extracted with CH2Cl2 (5 × 50 mL). The combined extracts
were evaporated to dryness under reduced pressure (at 30 °C), and
the residue was chromatographed on silica gel. Elution with 0−0.5%
MeOH/CH2Cl2 ﬁrst gave forerunners, and then further elution with
0.75−1% MeOH/CH2Cl2 gave R-155 (118 mg, 84%) as a cream solid:
mp (MeOH/CH2Cl2/hexane) 221−225 °C dec; 1H NMR
[(CD3)2SO] δ 8.27 (dd, J = 8.5, 1.6 Hz, 1 H), 8.26 (br s, 1 H),
8.11 (s, 1 H), 7.58 (br d, J = 7.0 Hz, 1 H), 7.35−7.25 (m, 2 H), 7.03
(ddd, J = 8.0, 7.7, 1.6 Hz, 1 H), 4.59 (dd, J = 11.3, 1.8 Hz, 1 H), 4.48
(ddd, J = 11.3, 3.0, 2.2 Hz, 1 H), 4.44−4.36 (m, 1 H), 4.31 (dd, J =
12.8, 4.1 Hz, 1 H), 4.12 (dt, J = 12.9, 2.1 Hz, 1 H); 13C NMR
[(CD3)2SO] δ 154.2, 147.0, 142.1, 136.7, 132.5, 127.8, 122.1, 121.1,
120.3, 120.2 (q, JC−F = 257.6 Hz), 118.4, 69.7, 47.8, 41.0. Anal. Calcd
for C14H12F3N5O5: C, 43.42; H, 3.12; N, 18.08. Found: C, 43.48; H,
2.99; N, 18.03.
Compounds of Table 4. The following section details the
synthesis of compound R-168 of Table 4, via representative
procedures and key intermediates, as described in Scheme 5. For
the syntheses of the other compounds in Table 4, see the Supporting
Information.
Synthesis of R-168 (Scheme 5D). (2R)-2-[(6-Bromopyridin-3-
yl)oxy]-3-[(4-methoxybenzyl)oxy]propan-1-ol (163). Reaction of 2-
bromo-5-({(2S)-1-[(4-methoxybenzyl)oxy]-3-[(triisopropylsilyl)oxy]-
propan-2-yl}oxy)pyridine42 (162) with TBAF (1.2 equiv), using
procedure C for 13 h (extracting the product four times with EtOAc),
followed by chromatography of the product on silica gel, eluting with
0−30% Et2O/petroleum ether and CH2Cl2 (forerunners) and then
with 2% MeOH/CH2Cl2, gave 163 (94%) as a white solid: mp
(CH2Cl2/pentane) 78−80 °C; 1H NMR (CDCl3) δ 8.12 (br d, J = 3.0
Hz, 1 H), 7.35 (br d, J = 8.7 Hz, 1 H), 7.20 (br d, J = 8.8 Hz, 2 H),
7.18 (dd, J = 8.7, 3.1 Hz, 1 H), 6.87 (br d, J = 8.7 Hz, 2 H), 4.51−4.42
(m, 3 H), 3.94−3.81 (m, 2 H), 3.81 (s, 3 H), 3.67 (d, J = 5.1 Hz, 2 H),
1.95 (t, J = 6.4 Hz, 1 H); [α]23D 19.8 (c 3.024, CHCl3). Anal. Calcd for
C16H18BrNO4: C, 52.19; H, 4.93; N, 3.80. Found: C, 52.19; H, 4.82;
N, 3.84.
Procedure O: 2-Bromo-5-({(2S)-1-iodo-3-[(4-methoxybenzyl)oxy]-
propan-2-yl}oxy)pyridine (164). A solution of iodine (3.74 g, 14.7
mmol) in anhydrous CH2Cl2 (9 × 10 mL) was slowly added
(dropwise over 1 h) to a stirred mixture of alcohol 163 (3.97 g, 10.8
mmol), imidazole (1.92 g, 28.2 mmol), and triphenylphosphine (3.70
g, 14.1 mmol) in anhydrous CH2Cl2 (50 mL) under N2 at 20 °C
(water bath cooling). After being stirred at 20 °C for 41 h, the mixture
was concentrated under reduced pressure (at 25 °C), and the residual
oil was added to excess petroleum ether (100 mL) at the top of a silica
gel column (50 g in petroleum ether), rinsing on with CH2Cl2 (4 × 5
mL). Elution with 0−10% Et2O/petroleum ether ﬁrst gave
forerunners, and then further elution with 20−33% Et2O/petroleum
ether gave 164 (5.17 g, 100%) as a colorless oil: 1H NMR (CDCl3) δ
8.11 (d, J = 3.1 Hz, 1 H), 7.36 (d, J = 8.7 Hz, 1 H), 7.22 (br d, J = 8.7
Hz, 2 H), 7.16 (dd, J = 8.7, 3.1 Hz, 1 H), 6.88 (br d, J = 8.7 Hz, 2 H),
4.51 (d, J = 11.6 Hz, 1 H), 4.48 (d, J = 11.6 Hz, 1 H), 4.37−4.30 (m, 1
H), 3.81 (s, 3 H), 3.73 (dd, J = 10.4, 5.2 Hz, 1 H), 3.69 (dd, J = 10.3,
4.9 Hz, 1 H), 3.43 (dd, J = 10.8, 5.5 Hz, 1 H), 3.36 (dd, J = 10.7, 5.4
Hz, 1 H); HRESIMS calcd for C16H18BrINO3 m/z [M + H]
+
479.9490, 477.9509, found 479.9489, 477.9508.
2-Bromo-5-({(2R)-1-(2-bromo-4-nitro-1H-imidazol-1-yl)-3-[(4-
methoxybenzyl)oxy]propan-2-yl}oxy)pyridine (165). A mixture of
iodide 164 (5.17 g, 10.8 mmol), 2-bromo-4-nitro-1H-imidazole (129)
(2.28 g, 11.9 mmol), and powdered K2CO3 (1.79 g, 13.0 mmol) in
anhydrous DMF (26 mL) under N2 was stirred at 88 °C for 122 h.
The resulting cooled mixture was added to aqueous NaHCO3 (100
mL) and extracted with CH2Cl2 (6 × 100 mL). The combined extracts
were evaporated to dryness under reduced pressure (at 30 °C), and
the residue was chromatographed on silica gel. Elution with 0−30%
EtOAc/petroleum ether ﬁrst gave forerunners, and then further
elution with 30−50% EtOAc/petroleum ether gave 165 (4.44 g, 76%)
as a pale yellow solid: mp (Et2O/pentane) 86−88 °C; 1H NMR
(CDCl3) δ 8.04 (d, J = 3.1 Hz, 1 H), 7.83 (s, 1 H), 7.37 (br d, J = 8.7
Hz, 1 H), 7.24 (br d, J = 8.7 Hz, 2 H), 7.02 (dd, J = 8.7, 3.2 Hz, 1 H),
6.92 (br d, J = 8.7 Hz, 2 H), 4.63−4.56 (m, 1 H), 4.53 (d, J = 11.6 Hz,
1 H), 4.49 (d, J = 11.6 Hz, 1 H), 4.46 (dd, J = 14.8, 3.8 Hz, 1 H), 4.36
(dd, J = 14.7, 7.1 Hz, 1 H), 3.84 (s, 3 H), 3.62 (dd, J = 10.5, 4.1 Hz, 1
H), 3.55 (dd, J = 10.5, 6.1 Hz, 1 H); HRESIMS calcd for
C19H18Br2N4NaO5 m/z [M + Na]
+ 566.9500, 564.9517, 562.9536,
found 566.9506, 564.9522, 562.9540.
(2R)-3-(2-Bromo-4-nitro-1H-imidazol-1-yl)-2-[(6-bromopyridin-3-
yl)oxy]propan-1-ol (166). A mixture of PMB ether 165 (4.42 g, 8.15
mmol) and DDQ (1.95 g, 8.59 mmol) in CH2Cl2 (175 mL) was
stirred at 20 °C for 48 h. Additional DDQ (202 mg, 0.89 mmol) was
added, and stirring was continued at 20 °C for 50 h. The resulting
mixture was added to saturated aqueous NaHCO3 (200 mL) and
extracted with CH2Cl2 (4 × 150 mL). The extracts were sequentially
washed with aqueous NaHCO3 (150 mL); then the combined extracts
were evaporated to dryness under reduced pressure (at 30 °C), and
the remaining oil was chromatographed on silica gel. Elution with
CH2Cl2 ﬁrst gave forerunners, and then further elution with 3%
MeOH/CH2Cl2 gave the crude product mixture (4.09 g) as a pale
yellow foam. This material was suspended in 3:1 MeOH/CH2Cl2 (200
mL) and treated with p-toluenesulfonic acid monohydrate (0.79 g,
4.15 mmol), stirring at 20 °C for 10 h. Excess NaHCO3 (0.5 g) was
added, and the mixture was concentrated under reduced pressure, then
diluted with aqueous NaHCO3 (100 mL), and extracted with CH2Cl2
(5 × 100 mL). The combined extracts were evaporated to dryness
under reduced pressure, and the remaining oil was chromatographed
on silica gel. Elution with 0−1% MeOH/CH2Cl2 ﬁrst gave
forerunners, and then further elution with 1−2% MeOH/CH2Cl2
gave 166 (3.32 g, 96%) as a cream solid: mp (MeOH/CH2Cl2/
hexane) 132−133 °C; 1H NMR [(CD3)2SO] δ 8.58 (s, 1 H), 8.08 (d,
J = 3.0 Hz, 1 H), 7.51 (br d, J = 8.7 Hz, 1 H), 7.36 (dd, J = 8.8, 3.2 Hz,
1 H), 5.25 (br t, J = 4.7 Hz, 1 H), 4.85−4.78 (m, 1 H), 4.44 (dd, J =
14.7, 3.9 Hz, 1 H), 4.37 (dd, J = 14.7, 7.8 Hz, 1 H), 3.72−3.57 (m, 2
H); [α]26D 13.3 (c 2.032, DMF). Anal. Calcd for C11H10Br2N4O4: C,
31.31; H, 2.39; N, 13.28. Found: C, 31.55; H, 2.32; N, 13.34.
(6R)-6-[(6-Bromopyridin-3-yl)oxy]-2-nitro-6,7-dihydro-5H-
imidazo[2,1-b][1,3]oxazine (167). A solution of alcohol 166 (3.29 g,
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7.80 mmol) in anhydrous DMF (50 mL) under N2 at 0 °C was treated
with 60% NaH (419 mg, 10.5 mmol) and then quickly degassed and
resealed under N2. The mixture was stirred at 0 °C for 45 min and
then at 20 °C for 160 min, then cooled to −78 °C (CO2/acetone), the
reaction quenched with ice/aqueous NaHCO3 (20 mL), and the
mixture added to brine (200 mL). The resulting mixture was
sequentially extracted with CH2Cl2 (150 mL), 10% MeOH/CH2Cl2
(4 × 150 mL), 20% EtOAc/CH2Cl2 (4 × 150 mL), 25% MeOH/
CH2Cl2 (4 × 150 mL), CH2Cl2 (2 × 150 mL), and EtOAc (150 mL),
and then the combined extracts were evaporated to dryness under
reduced pressure (at 30 °C). The crude residue was triturated in water,
ﬁltered and dried, then resuspended in warm 5% MeOH/CH2Cl2 (100
mL), cooled, and ﬁltered to give 167 (1.93 g, 73%) as a pale brown
solid: mp 244−247 °C; 1H NMR [(CD3)2SO] δ 8.22 (br d, J = 3.0 Hz,
1 H), 8.05 (s, 1 H), 7.61 (br d, J = 8.6 Hz, 1 H), 7.55 (dd, J = 8.8, 3.1
Hz, 1 H), 5.35−5.29 (m, 1 H), 4.69 (dt, J = 12.4, 2.1 Hz, 1 H), 4.64
(br d, J = 12.2 Hz, 1 H), 4.40 (dd, J = 14.0, 3.0 Hz, 1 H), 4.35 (br d, J
= 14.1 Hz, 1 H); [α]25D 21.0 (c 1.000, DMF). Anal. Calcd for
C11H9BrN4O4: C, 38.73; H, 2.66; N, 16.42. Found: C, 38.67; H, 2.54;
N, 16.40.
The ﬁltrate described above was evaporated to dryness under
reduced pressure, and the residue was chromatographed on silica gel.
Elution with 0−0.5% MeOH/CH2Cl2 ﬁrst gave forerunners, and then
further elution with 0.5−0.67% MeOH/CH2Cl2 gave the crude
product, which was suspended in warm 10% MeOH/CH2Cl2 (15 mL),
then diluted with CH2Cl2 (20 mL) and hexane (50 mL), and ﬁltered
to give additional 167 (233 mg, 9%).
(6R)-2-Nitro-6-({6-[4-(triﬂuoromethoxy)phenyl]pyridin-3-yl}oxy)-
6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (R-168). Reaction of
bromide 167 with Pd(dppf)Cl2 (0.27 equiv) and [4-
(triﬂuoromethoxy)phenyl]boronic acid (1.9 equiv), using procedure
I for 210 min, followed by chromatography of the product on silica gel,
eluting with 0−0.33% MeOH/CH2Cl2 (forerunners) and then with
0.5% MeOH/CH2Cl2, gave R-168 (86%) as a cream solid: mp
(MeOH/CH2Cl2/hexane) 239−241 °C; 1H NMR [(CD3)2SO] δ 8.46
(d, J = 2.9 Hz, 1 H), 8.16 (br d, J = 8.9 Hz, 2 H), 8.08 (s, 1 H), 8.01
(d, J = 8.7 Hz, 1 H), 7.67 (dd, J = 8.8, 3.0 Hz, 1 H), 7.45 (br d, J = 8.1
Hz, 2 H), 5.44−5.36 (m, 1 H), 4.73 (dt, J = 12.4, 2.1 Hz, 1 H), 4.69
(br d, J = 12.0 Hz, 1 H), 4.45 (dd, J = 13.9, 3.0 Hz, 1 H), 4.39 (br d, J
= 14.0 Hz, 1 H); 13C NMR [(CD3)2SO] δ 151.9, 148.5 (q, JC−F = 1.4
Hz), 148.3, 146.9, 142.2, 138.8, 137.4, 127.9 (2 C), 123.9, 121.2 (2 C),
121.1, 120.1 (q, JC−F = 256.4 Hz), 118.0, 67.9, 66.0, 46.3; [α]
25
D 6.98
(c 1.003, DMF). Anal. Calcd for C18H13F3N4O5: C, 51.19; H, 3.10; N,
13.27. Found: C, 51.33; H, 2.94; N, 13.27.
Minimum Inhibitory Concentration Assays (MABA and
LORA). These assays against M. tb were performed according to the
reported procedures.59,60 Results in Table 1 are the mean of two or
three independent determinations (SD data are given in Table S1).
In Vitro Parasite Growth Inhibition Assays. The activity of test
compounds against the amastigote stage of the L. don parasite was
measured at CDRI using a mouse macrophage-based luciferase assay,
performed according to the published procedures.26 Replicate assays
quantifying the growth inhibitory action of compounds against L. inf,
T. cruzi, and T. brucei and assessing any cytotoxic eﬀects on human
lung ﬁbroblasts (MRC-5 cells) were conducted at the University of
Antwerp (LMPH), as previously described;44 results in Tables 1−4 are
the mean of at least two (up to 10) independent determinations (SD
data are given in Tables S1−S4). Additional assays using a wider range
of VL and CL strains and clinical isolates were performed via
comparable methods at LMPH44 or LSHTM26 (primary peritoneal
mouse macrophages infected with cultured promastigotes were
incubated at 37 °C for 24 h prior to the addition of test compounds
and then further incubated for either 3 or 5 days for CL or VL assays,
respectively).
Solubility Determinations. Method A. The solid compound
sample was mixed with water or 0.1 M HCl (enough to make a 2 mM
solution) in an Eppendorf tube, and the suspension was sonicated for
15 min and then centrifuged at 13000 rpm for 6 min. An aliquot of the
clear supernatant was diluted 2-fold with water (or 0.1 M HCl), and
then HPLC was performed (as described). The kinetic solubility was
calculated by comparing the peak area obtained with that from a
standard solution of the compound in DMSO (after allowing for
varying dilution factors and injection volumes).
Method B. The thermodynamic solubility of compound R-6 at pH
7.4 was measured by Syngene International Ltd. (Plot No. 2 and 3
Biocon Park, Jigani Link Road, Bangalore 560099, India). The dry
powder was equilibrated with 0.1 M phosphate buﬀer (pH 7.4) in a
glass vial at 25 °C (water bath), shaking for 24 h. After ﬁltration using
a 0.45 μm PVDF membrane ﬁlter, the concentration of R-6 was
determined by HPLC (Waters e2695 system, employing a 150 mm ×
4.6 mm XBridge 3.5 μm reversed phase C18 column and isocratic
elution with 50% CH3CN in 10 mM ammonium acetate buﬀer, at 1
mL/min), comparing the peak area obtained with that from a standard
solution (0.93 mM) in 1:1:2 EtOH/water/CH3CN.
Microsomal Stability Assays. Compound 22 was tested by MDS
Pharma Services (22011 30th Dr. SE, Bothell, WA 98021-4444), as
described previously.47 Studies of compounds 24, S-51, S-77, R-77, S-
81, R-81, R-84, S-89, R-89, S-91, R-91, S-92, R-92, R-94, 116, 117, S-
151, and S-155 (Table 5) were run by Advinus Therapeutics Ltd. (21
and 22 Phase II, Peenya Industrial Area, Bangalore 560058, India),
using a published procedure61 in which the compound concentration
was 0.5 μM and the incubation time was 30 min. Additional analyses
of compounds R-1, R-6, R-69, R-74, R-84, R-89, R-91, R-92, R-94, R-
96, R-99, R-102, R-106, R-136, R-147, R-151, R-168, and R-169 were
performed by WuXi AppTec (Shanghai) Co., Ltd. (288 FuTe
ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai 200131, China)
via a reported25 method; the compound concentration was 1 μM, and
the incubation time was 1 h.
Distribution Coeﬃcient. This was measured by WuXi AppTec
(Shanghai) Co., Ltd. The LogD value of R-6 was found by assessing its
distribution between 100 mM phosphate buﬀer (pH 7.4) and octanol
at room temperature (ﬁnal matrix contained 1% DMSO), using the
shake-ﬂask method and LC−MS/MS analysis.
Permeability Assay. The assay was performed by WuXi AppTec
(Shanghai) Co., Ltd. MDCK-MDR1 cells were seeded onto
polyethylene membranes in 96-well plates at a density of 2 × 105
cells/cm2, giving conﬂuent cell monolayer formation over 4−7 days. A
solution of R-6 (2 μM in 0.4% DMSO/HBSS buﬀer) was applied to
the apical or basolateral side of the cell monolayer. Permeation of the
compound in the A to B direction or B to A direction was assessed in
triplicate over a 150 min incubation at 37 °C and 5% CO2 (95%
humidity). In addition, the eﬄux ratio of R-6 was also determined.
Test and reference compounds were quantiﬁed by LC−MS/MS
analysis based on the peak area ratio of the analyte/internal standard.
Plasma Protein Binding Assays. The studies of 4 and R-6 were
performed by WuXi AppTec (Shanghai) Co., Ltd., using equilibrium
dialysis across a semipermeable membrane. Brieﬂy, 2 μM compound
solutions in plasma were dialyzed against 100 mM phosphate-buﬀered
saline (pH 7.4) on a rotating plate (150 rpm) incubated at 37 °C for 4
or 6 h. Following precipitation of protein with CH3CN, the amount of
compound present in each compartment was quantiﬁed by LC−MS/
MS; values are the mean of triplicate determinations.
Ames Test. Compounds R-6 and R-136 (at doses of 1.5, 4, 10, 25,
64, 160, 400, and 1000 μg/well) were evaluated in triplicate in the
Mini-Ames reverse mutation screen conducted by WuXi AppTec
(Suzhou) Co., Ltd. (1318 Wuzhong Ave., Wuzhong District, Suzhou
215104, China). Two strains of Salmonella typhimurium (TA98 and
TA100) were employed, in the presence and absence of metabolic
activation (rat liver S9). Positive controls (2-aminoanthracene, 2-
nitroﬂuorene, and sodium azide) and a negative (DMSO solvent)
control were included.
hERG Assay. The eﬀects of compounds R-6, R-84, R-89, and R-
136 on cloned hERG potassium channels expressed in Chinese
hamster ovary cells were assessed by WuXi AppTec (Shanghai) Co.,
Ltd., using the automated patch clamp method. Six concentrations
(0.12, 0.37, 1.11, 3.33, 10, and 30 μM) were tested (at room
temperature), and at least three replicates were obtained for each.
CYP3A4 Inhibition Assay. This work was performed by WuXi
AppTec (Shanghai) Co., Ltd. Compound R-6 (at concentrations of 1
and 10 μM) was incubated with NADPH-fortiﬁed pooled HLM (0.2
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mg/mL) and testosterone (50 μM) in phosphate buﬀer (100 mM) at
37 °C for 10 min. Following quenching with CH3CN, samples were
analyzed for the formation of 6β-hydroxytestosterone by LC−MS/MS,
and the percentage inhibition was determined (ketoconazole was the
positive control, and tolbutamide was used as an internal standard).
In Vivo Experiments. All animal experiments were performed
according to institutional ethical guidelines for animal care. Mouse
model studies (LSHTM) were conducted under license (PPL
X20014A54), according to UK Home Oﬃce regulations, Animals
(Scientiﬁc Procedures) Act 1986, and European Directive 2010/63/
EU, and hamster studies (LMPH) were approved by the ethical
committee of the University of Antwerp (UA-ECD 2010−17).
Acute VL Infection Assay (mouse model, LSHTM). Test
compounds were orally administered once per day for 5 days
consecutively to groups of ﬁve female BALB/c mice infected with 2 ×
107 L. don amastigotes, with treatment commencing 1 week
postinfection, as described previously.26 Miltefosine and AmBisome
were positive controls, and parasite burdens were determined from
impression smears of liver sections. Eﬃcacy was expressed as the mean
percentage reduction in parasite load for treated mice in comparison to
untreated (vehicle-only) controls (SD data are provided in Table S5).
Derived ED50 values (with 95% conﬁdence limits, as speciﬁed in Table
S5) were obtained from GraphPad Prism 6 software, using a four-
parametric sigmoidal variable slope dose−response curve.
Chronic VL Infection Assay (hamster model, LMPH). Golden
hamsters (weighing 75−80 g) were infected with 2 × 107 L. inf
amastigotes, and 21 days postinfection, treatment groups of six animals
each were treated orally twice per day with test compounds
(formulated in PEG-400) for 5 days consecutively. Parasite burdens
in three target organs (liver, spleen, and bone marrow) were
determined by microscopic evaluation of impression smears (stained
with Giemsa), and eﬃcacy was expressed as the mean percentage
parasite load reduction for treated hamsters in comparison to
untreated (vehicle-only) controls (SD data are given in Table S6).
Miltefosine was included as a reference drug in all experiments.
Mouse Pharmacokinetics. Testing of compounds 24, 116, and
117 was executed by Advinus Therapeutics Ltd., according to a
published protocol.61 Brieﬂy, compounds were administered to groups
of male Swiss albino mice; intravenous dosing (at 1 mg/kg) employed
a solution vehicle comprising 20% NMP and 40% PEG-400 in 100
mM citrate buﬀer (pH 3), while oral dosing (at 25 mg/kg) was as a
suspension in 0.5% carboxymethylcellulose (CMC) and 0.08% Tween
80 in water. Samples derived from plasma (at 0.083 for iv only, 0.25,
0.5, 1, 2, 4, 6, 8, 10, 24, and 48 h) were centrifuged prior to analysis by
LC−MS/MS, and the PK parameters were determined using Phoenix
WinNonlin software (version 5.2). The remaining compounds (R-6,
R-84, R-89, and R-136) were assessed by WuXi AppTec (Shanghai)
Co., Ltd.; in this case, oral dosing of female BALB/c mice occurred at
40−50 mg/kg in PEG-400 (sampling at 0.25, 1, 2, 4, 8, and 24 h), and
the PK data were obtained using WinNonlin software (version 6.2)
following similar LC−MS/MS analysis.
Rat and Hamster Pharmacokinetics. All studies were conducted
in fasted animals (either male Sprague-Dawley rats or female golden
Syrian hamsters) by WuXi AppTec (Shanghai) Co., Ltd. Intravenous
dosing (at 1 mg/kg for rats and 2 mg/kg for hamsters) utilized a
solution formulation of 20% NMP and 40% PEG-400 in citrate buﬀer
(pH 3). In rats, oral dosing (at 40−50 mg/kg) was as a suspension in
0.08% Tween 80 and 0.5% CMC in water, whereas PEG-400 was the
vehicle employed for oral dosing in hamsters (at 40−50 mg/kg).
Plasma samples (at 0.083 for iv only, 0.25, 0.5, 1, 2, 4, 8, and 24 h)
were analyzed by LC−MS/MS, and the PK parameters were calculated
using Phoenix WinNonlin software (version 6.3).
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